

PA 1124576

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 06, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/439,767

FILING DATE: January 13, 2003

REC'D 09 MAR 2004

WIPO PCT

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

P. SWAIN  
Certifying Officer

BEST AVAILABLE COPY

PET/AU04/43

01/13/03  
JC945 U.S. PTO

01-14-03

6043767 .011303 APR


Please type a plus sign (+) inside this box ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0851-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

# **PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

INVENTOR(S)					
Given Name (first and middle (if any))		Family Name or Surname		Residence (City and either State or Foreign Country)	
Greg Ken David Victoria C.		Collier Walder Segal Foletta		Victoria, Australia Victoria, Australia Victoria, Australia Victoria, Australia	
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
A Novel Gene And Uses Therefor					
Direct all correspondence to:					
<input type="checkbox"/> Customer Number				ADDRESS	
OR		Type Customer Number here		<div style="border: 1px solid black; padding: 5px;">           Place Customer Number Bar Code Label here         </div>	
<input type="checkbox"/> Firm or Individual Name		Reed Smith LLP			
Address		One Liberty Place			
Address		1650 Market Street			
City		Philadelphia		State	PA
Country		US		ZIP	19103
		Telephone	215-851-8100	Fax	215-851-1420
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		104		<input type="checkbox"/> CD(s), Number	
<input type="checkbox"/> Drawing(s) Number of Sheets		20		<input checked="" type="checkbox"/> Other (specify)	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		Sequence Listing			
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)					
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees				FILING FEE AMOUNT (\$)	
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number		18-0586		\$160.00	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:					

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME William J. McNichol Jr.

TELEPHONE 215-241-7950

Date 1/13/2003

REGISTRATION NO. 31,179  
(if appropriate)  
Docket Number: 03-40003-PR

## **USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C.

P19LARGE/REV05

**ReedSmith**

Carl H. Pierce • 215 241 7970 • cpierce@reedsmith.com

January 13, 2003

Commissioner for Patents  
BOX Provisional Application  
Washington, D.C. 20231

Re: New Provisional Application  
For: "A Novel Gene And Uses Therefor"  
File Date: January 13, 2003  
Our Reference: 03-40003-PR

Dear Sir:

Enclosed for filing in connection with the above-referenced provisional patent application are the following documents:

1. Specification (104 pages);
2. Drawings (20 pages);
3. Sequence Listing (11 pages)
4. Provisional Application Cover Sheet (in duplicate); and
5. A self-addressed stamped postcard, return of which is requested to acknowledge receipt of the enclosed documents.

**EXPRESS MAIL CERTIFICATE (37 CFR 1.10)**

Express Mail Label No. : EL 598359553 US

Date of Deposit January 13, 2003

I hereby certify that this paper, and the papers and/or fees referred to herein as transmitted, submitted or enclosed, are being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Name: Elaine Weisbecker

Signature



Kindly acknowledge receipt of these documents by returning the enclosed self-addressed, stamped postcard to me. The Commissioner is hereby authorized to charge any additional fees required in connection with this filing to Account No. 18-0586.

Very truly yours,

REED SMITH LLP.

  
William J. McNichol, Jr.

Enclosures

2500 One Liberty Place  
1650 Market Street  
Philadelphia, PA 19103-7301  
215.851.8100  
Fax 215.851.1420

Delaware  
New Jersey  
New York  
Pennsylvania  
Virginia  
Washington, DC

Formed in the Commonwealth of Pennsylvania

r e e d s m i t h . c o m

PHUB-0566781.01-TAMCKXHL  
January 13, 2003 3:01 PM

- 1 -

## A NOVEL GENE AND USES THEREFOR

### BACKGROUND OF THE INVENTION

#### 5 FIELD OF THE INVENTION

The present invention relates generally to a nucleic acid molecule which is expressed in at least red gastrocnemius muscle of *Psammomys obesus* under particular physiological conditions. It is proposed that the nucleic acid molecule is differentially expressed under  
10 differing conditions of obesity, anorexia, weight maintenance, diabetes and/or metabolic energy levels. More particularly, the present invention uses microarray technology to identify genes which are expressed under particular physiological conditions. It is proposed that the subject nucleic acid molecule and/or its expression product be used in therapeutic and diagnostic protocols for conditions such as obesity, anorexia, weight maintenance, diabetes  
15 and/or energy imbalance. The subject nucleic acid molecule and its expression product or derivatives, homologs, analogs and mimetics thereof are proposed to be useful, therefore, as therapeutic and diagnostic agents for obesity, anorexia, weight maintenance, diabetes and/or energy imbalance or as targets for the design and/or identification of modulators of their activity and/or function.

20

#### DESCRIPTION OF THE PRIOR ART

Bibliographic details of references provided in the subject specification are listed at the end of the specification.

25

Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country.

- 2 -

The increasing sophistication of recombinant DNA technology is greatly facilitating research and development in the medical, veterinary and allied human and animal health fields. This is particularly the case in the investigation of the genetic bases involved in the etiology of certain disease conditions. One particularly significant condition from the stand point of morbidity and mortality is obesity and its association with type 2 diabetes (formerly non-insulin-dependent diabetes mellitus or NIDDM) and cardiovascular disease.

Obesity is defined as a pathological excess of body fat and is the result of an imbalance between energy intake and energy expenditure for a sustained period of time. Obesity is the most common metabolic disease found in affluent societies. The prevalence of obesity in these nations is alarmingly high, ranging from 10% to upwards of 50% in some sub-populations (Bouchard, *The genetics of Obesity*, Boca Raton: CRC Press, 1994). Of particular concern is the fact that the prevalence of obesity appears to be rising consistently in affluent societies and is now increasing rapidly in less prosperous nations as they become more affluent and/or adopt cultural practices similar to those in more affluent countries (Zimmet, *Diabetes Care* 15: 232-252, 1992). The escalating rates of obesity globally have resulted in the World Health Organisation declaring an obesity epidemic worldwide (World Trade Organisation. Obesity. Preventing and managing the global epidemic. Report of a WHO Consultation on Obesity. Geneva: World Health Organisation, 1998).

20

In Australia, the recent AusDiab study estimated that 7.5 million Australians (60%) aged 25 years and over were overweight or obese. Of these, 2.6 million (21%) were obese (BMI>30) (Dunstan *et al.*, *Diabetes Res. Clin. Pract.* 57: 119-129, 2002). Similarly, the prevalence of obesity in the U.S. increased substantially between 1991 and 1998, increasing from 12% to 18% in Americans during this period (Mokdad *et al.*, *JAMA* 282(16): 1519-1522, 1999).

25

The high and increasing prevalence of obesity has serious health implications for both individuals and society as a whole. Obesity is a complex and heterogeneous disorder and has been identified as a key risk indicator of preventable morbidity and mortality as obesity

increases the risk of a number of other metabolic conditions including type 2 diabetes mellitus and cardiovascular disease (Must *et al.*, *JAMA* 282(16): 1523-1529, 1999; Kopelman, *Nature* 404: 635-643, 2000). Alongside obesity the prevalence of diabetes continues to increase rapidly. The AusDiab survey estimated that close to 1 million Australians aged 25 years and  
5 over have type 2 diabetes (Dunstan *et al.*, 2002). This represents approximately 7.5% of the population. In the U.S., the number of adults with diabetes increased by 49% between 1991 and 2000 (Marx, *Science* 686-689, 2002). It has been estimated that about 17 million people in the U.S. have type 2 diabetes and an equal number are thought to be pre-diabetic (Marx, 2002). In Australia, the annual costs of obesity associated with diabetes and other disease  
10 conditions has been conservatively estimated to be AUS\$810million for 1992-93 (National Health and Medical Research Council, *Acting on Australia's weight: A strategy for the prevention of overweight and obesity*. Canberra: National Health and Medical Research Council, 1996). The direct costs of diabetes and its complications in Australia in 1993-94 were estimated at \$681 million, or 2.2% of total health system costs in that year (Australian Institute  
15 of Health and Welfare (AIWH), *Australia's Health*, 2002, Canberra: AIWH).

A genetic basis for the etiology of obesity is indicated *inter alia* from studies in twins, adoption studies and population-based analyses which suggest that genetic effects account for 25-80% of the variation in body weight in the general population (Bouchard, 1994, *supra*;  
20 Kopelman *et al.*, *Int. J. Obesity* 18: 188-191, 1994; Ravussin, *Metabolism* 44(3): 12-14, 1995). It is considered that genes determine the possible range of body weight in an individual and then the environment influences the point within this range where the individual is located at any given time (Bouchard, 1994). However, despite numerous studies into genes thought to be involved in the pathogenesis of obesity, there have been surprisingly few significant  
25 findings in this area. In addition, genome-wide scans in various population groups have not produced definitive evidence of the chromosomal regions having a major effect on obesity.

A number of tissues have been implicated in the pathophysiology of obesity and type 2 diabetes, and of particular interest is the muscle. Skeletal muscle is the principle site of

- 4 -

insulin-stimulated glucose disposal, accounting for approximately 75% of total glucose uptake. Skeletal muscle is also the major site of peripheral insulin resistance. Skeletal muscle also oxidizes free fatty acids for fuel, to meet its energy requirements. In healthy individuals, the muscle has the capacity to utilize both carbohydrate and lipids for energy and to fluctuate  
5 between these fuels in response to a range of signals including insulin concentrations. This metabolic flexibility is central to the role the muscle plays in whole body fuel metabolism and with diseases such as obesity and type 2 diabetes, this flexibility may be lost.

In accordance with the present invention, genetic sequences were sought which are expressed  
10 in at least red gastrocnemius muscle of *Psammomys obesus* (Israeli Sand Rat) under particular physiological conditions. Novel genes are identified which have human and/or murine equivalents or homologs. In accordance with the present invention, genes are isolated which are proposed to be associated with one or more biological functions associated with disease conditions such as but not limited to obesity, anorexia, diabetes or energy balance.

- 5 -

## SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a  
5 stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Nucleotide and amino acid sequences are referred to by a sequence identifier number (SEQ ID NO:). The SEQ ID NOs: correspond numerically to the sequence identifiers <400>1 (SEQ ID  
10 NO:1), <400>2 (SEQ ID NO:2), etc. A summary of the sequence identifiers is provided in Table 3. A sequence listing is provided after the claims. A summary of genes identified in accordance with the present invention is provided in Table 1. Gene abbreviations are provided in Table 2.

15 Analysis of genetic material from red gastrocnemius muscle tissue were used to identify candidate genetic sequences associated with a healthy state or with physiological conditions such as obesity, anorexia, weight maintenance, diabetes and/or metabolic energy levels. An animal model was employed comprising the Israeli Sand Rat (*Psammomys obesus*). Three groups of animals were used designated Groups A, B and C based on metabolic phenotype as  
20 follows:-

- Group A: lean animals (normoglycemic; normoinsulinemic);
- Group B: obese, non-diabetic animals (normoglycemic; hyperinsulinemic); and
- Group C: obese, diabetic animals (hyperglycemic; hyperinsulinemic).

25

Microarray analysis was used to identify genetic sequences in fed and fasted mammals or in exercise trained and control mammals. The Israeli Sand Rat (*Psammomys obesus*) was found to be particularly useful for this analysis.

- 6 -

cDNA microarray technology provides a powerful technical means to generate a gene expression database of both known genes and unknown transcripts. Using cDNA microarrays, comparative estimates can be obtained of the level of gene expression of large numbers of genes (up to 20,000 per microarray) in each sample. cDNA microarrays generally involve a large number of DNA "spots" in an orderly array chemically coupled to the surface of a solid substrate, usually but not exclusively an optically flat glass microscope slide. Fluorescently labeled cDNAs are generated from experimental and reference RNA samples and then competitively hybridized to the gene chip. The experimental and reference cDNAs are labeled with a different fluorescent dye and the intensity of each fluor at each DNA spot gives an indication of the level of that particular RNA species in the experimental sample relative to the reference RNA. The ratio of fluorescence can be taken as a measure of the expression level of the gene corresponding to that spot in the experimental sample.

In a preferred embodiment, nine expressed sequences were identified designated herein *AGT-701* [SEQ ID NO:1], *AGT-702* [SEQ ID NO:2], *AGT-704* [SEQ ID NO:3], *AGT-705* [SEQ ID NO:4], *AGT-706* [SEQ ID NO:5], *AGT-707* [SEQ ID NO:6], *AGT-708* [SEQ ID NO:7], *AGT-709* [SEQ ID NO:8] and *AGT-710* [SEQ ID NO:9].

A summary of the AGT genes is provided in Table 1.

20

The present invention contemplates the use of these sequences or their expression products in the manufacture of medicaments and diagnostic agents for a range of conditions including obesity, anorexia, weight maintenance, diabetes and/or energy imbalance.

25 The present invention provides, therefore, a nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding an expression product or a derivative, homolog, analog or mimetic thereof wherein said nucleic acid molecule or its homolog is differentially expressed in red gastrocnemius of *P. obesus* under fed or fasted or in exercise trained and control conditions.

- 7 -

The present invention further provides a nucleic acid molecule comprising a nucleotide sequence encoding or complementary to a sequence encoding an expression product or a derivative, homolog, analog or mimetic thereof wherein the nucleotide sequence is as substantially set forth in SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or  
5 SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 or a nucleotide sequence having at least about 30% similarity to all or part of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 and/or is capable of hybridizing to one or more of  
10 SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 or their complementary forms under low stringency conditions at 42°C and wherein the nucleic acid molecule is differentially expressed in red gastrocnemius tissue of *P. obesus* under fed or fasted or in exercise trained and control conditions.

15

The present invention also provides an isolated expression product or a derivative, homolog, analog or mimetic thereof which expression product is encoded by a nucleotide sequence which is differentially expressed in red gastrocnemius tissue of *P. obesus* under fed or fasted or in exercise trained and control conditions.

20

More particularly, the present invention is directed to an isolated expression product or a derivative, homolog, analog or mimetic thereof wherein the expression product is encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8  
25 or SEQ ID NO:9 or a nucleotide sequence having at least 30% similarity to all or part of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 and/or is capable of hybridizing to SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 or their complementary forms under low

- 8 -

stringency conditions at 42°C.

The preferred genetic sequence of the present invention are referred to herein as *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710*. The  
5 expression products encoded by *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* are referred to herein as *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710*, respectively. The expression product may be an RNA (e.g. mRNA) or a protein. Where the expression product is an RNA, the present invention extends to RNA-related molecules associated thereto such as  
10 RNAi or intron or exon sequences therefrom.

Even yet another aspect of the present invention relates to a composition comprising *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710* or its derivatives, homologs, analogs or mimetics or agonists or antagonists of *AGT-701*,  
15 *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710* together with one or more pharmaceutically acceptable carriers and/or diluents.

The present invention is particularly directed to human homologs of the genes identified in *P. obesus* and their use in therapy and diagnosis.

20 Another aspect of the present invention contemplates, therefore, a method for treating a subject comprising administering to said subject a treatment effective amount of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710* or a derivative, homolog, analog or mimetic thereof or a genetic sequence encoding same or  
25 an agonist or antagonist of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710* activity or *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710* gene expression for a time and under conditions sufficient to effect treatment.

- 9 -

In accordance with this and other aspects of the present invention, treatments contemplated herein include but are not limited to obesity, anorexia, weight maintenance, energy imbalance and diabetes. Treatment may be by the administration of a pharmaceutical composition or genetic sequences *via* gene therapy. Treatment is contemplated for human subjects as well as  
5 animals such as animals important to livestock industry.

A further aspect of the present invention is directed to a diagnostic agent for use in monitoring or diagnosing conditions such as but not limited to obesity, anorexia, weight maintenance, energy imbalance and/or diabetes, said diagnostic agent selected from an antibody to AGT-  
10 701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and/or AGT-710 or its derivatives, homologs, analogs or mimetics and a genetic sequence comprising or capable of annealing to a nucleotide strand associated with *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* or *AGT-710* useful *inter alia* in PCR, hybridization, RFLP analysis or AFLP analysis.

**TABLE 1**  
**Summary of AGT Genes**

GENE	SEQ ID NO	HOMOLOG	DESCRIPTION
AGT-701	1	human, mouse and rat NDRG2	lower expression in Group C, fed animals and higher expression in Group B fasted animals; expression negatively correlated with body fat, body weight and blood glucose in fed animals; increases with exercise training
AGT-702	2	human, mouse and rat PRSS11	elevated expression after training; negative correlation with body weight and blood glucose; positive correlation with energy expenditure
AGT-704	3	human PAI-RBP1	decreased expression in Group C, fed animals; negative correlation with blood glucose in fed animals; increases with exercise training
AGT-705	4	murine BC030414	increased expression in Group C animals and in Group B fasted animals; expression negatively correlated with blood glucose; increases with exercise training
AGT-706	5	human FL520069 murine Ahi-1	elevated expression in Group B fasted and Group C fasted animals; expression negatively correlated with blood glucose in fed animals and positively correlated in insulin in fasted animals; increases with exercise training
AGT-707	6	human ASNA1	elevated expression in Group A animals; expression negatively correlated with body weight in fed animals; increases with exercise training
AGT-708	7	human PKIA	elevated expression in Group B and Group C fasted animals; expression positively correlated with blood glucose

- 11 -

GENE	SEQ ID NO	HOMOLOG	DESCRIPTION
AGT-709	8	human KIAA0633, Mus musculus similar to KIAA0633	lower expression in Group C, fed animals; expression negatively correlated with body weight and blood glucose
AGT-710	9	human, mouse and rat SCP2	lower expression in Group C, fed animals; expression negatively correlated with body weight and blood glucose in fed animals; increases with exercise training

- 12 -

**TABLE 2**  
***Gene Abbreviations***

ABBREVIATION	DEFINITION
NDRG2	N-myc downstream-regulated gene 2
PRSS11	protease, serine 11
PAI-RBP1	PAI-1 mRNA binding protein
ASNA1	human homolog of bacterial arsA arsenite transporter ATP binding
PKIA	protein kinase inhibitor alpha
SCP2	sterol carrier protein 2

- 13 -

A summary of sequence identifiers used throughout the subject specification is provided in Table 3.

**TABLE 3*****Summary of Sequence Identifiers***

5

SEQUENCE ID NO.	DESCRIPTION
1	Nucleotide sequence of <i>AGT-701</i>
2	Nucleotide sequence of <i>AGT-702</i>
3	Nucleotide sequence of <i>AGT-704</i>
4	Nucleotide sequence of <i>AGT-705</i>
5	Nucleotide sequence of <i>AGT-706</i>
6	Nucleotide sequence of <i>AGT-707</i>
7	Nucleotide sequence of <i>AGT-708</i>
8	Nucleotide sequence of <i>AGT-709</i>
9	Nucleotide sequence of <i>AGT-710</i>
10	primer SP6
11	primer T7
12	peptide
13	peptide

**BRIEF DESCRIPTION OF THE DRAWINGS**

**Figure 1** is a graphical representation showing *AGT-701* gene expression in *P. obesus* red gastrocnemius muscle after exercise. \* $p < 0.001$ .

5

**Figure 2** is a graphical representation of *AGT-701* gene expression *versus* blood glucose in all animals.

**Figure 3** is a graphical representation of *AGT-701* gene expression *versus* change in blood glucose in all animals.

10

**Figure 4** is a graphical representation of *AGT-701* gene expression *versus* energy expenditure in all animals.

**Figure 5** is a graphical representation showing *AGT-701* gene expression in fed animals. \* $p = 0.011$ .

15

**Figure 6** is a graphical representation showing expression of *AGT-701* in fasted animals. \* $p = 0.04$ .

20

**Figure 7** is a graphical representation showing expression of *AGT-701* *versus* percent body fat in fed animals.

**Figure 8** is a graphical representation showing expression of *AGT-701* *versus* body weight in fed animals.

25

**Figure 9** is a graphical representation showing expression of *AGT-701* *versus* blood glucose in fed animals.

- 15 -

**Figure 10** is a graphical representation of *AGT-702* gene expression in *P. obesus* red gastrocnemius muscle after exercise. \* $p < 0.001$ .

**Figure 11** is a graphical representation of *AGT-702* gene expression *versus* body weight in exercise trained animals.

**Figure 12** is a graphical representation of *AGT-701* gene expression *versus* energy expenditure in all animals.

**Figure 13** is a graphical representation of *AGT-702* gene expression *versus* blood glucose in all animals.

**Figure 14** is a graphical representation of *AGT-702* gene expression *versus* change in blood glucose in all animals.

**Figure 15** is a graphical representation of *AGT-704* gene expression in *P. obesus* red gastrocnemius muscle after exercise. \* $p < 0.001$ .

**Figure 16** is a graphical representation of *AGT-704* gene expression *versus* blood glucose in all animals.

**Figure 17** is a graphical representation of *AGT-704* gene expression *versus* energy expenditure in all animals.

**Figure 18** is a graphical representation of *AGT-704* gene expression in fed animals.

**Figure 19** is a graphical representation of *AGT-704* gene expression *versus* blood glucose in fed animals.

- 16 -

**Figure 20** is a graphical representation of *AGT-705* gene expression in *P. obesus* red gastrocnemius muscle after exercise.

**Figure 21** is a graphical representation of *AGT-705* gene expression in fed animals.

5

**Figure 22** is a graphical representation of *AGT-705* gene expression in fasted animals. \*p = 0.035, #p = 0.007.

**Figure 23** is a graphical representation of *AGT-705* gene expression *versus* blood glucose in  
10 fasted animals.

**Figure 24** is a graphical representation of *AGT-706* gene expression in *P. obesus* red gastrocnemius muscle after exercise. \*p = 0.001.

15 **Figure 25** is a graphical representation of *AGT-706* gene expression *versus* blood glucose in all animals.

**Figure 26** is a graphical representation of *AGT-706* gene expression *versus* insulin in all animals.

20

**Figure 27** is a graphical representation of *AGT-704* gene expression *versus* energy expenditure in all animals.

**Figure 28** is a graphical representation of *AGT-706* gene expression in fasted animals. \*p < 25 0.001, #p < 0.001.

**Figure 29** is a graphical representation of *AGT-706* gene expression *versus* blood glucose in fed animals.

- 17 -

Figure 30 is a graphical representation of *AGT-706* gene expression *versus* insulin in fasted animals.

Figure 31 is a graphical representation of *AGT-707* gene expression in *P. obesus* red gastrocnemius muscle after exercise. \* $p = 0.037$ .

Figure 32 is a graphical representation of *AGT-707* gene expression in fed animals.

Figure 33 is a graphical representation of *AGT-707* gene expression *versus* body weight in fed animals.

Figure 34 is a graphical representation of *AGT-708* gene expression *versus* activity in all animals.

Figure 35 is a graphical representation of *AGT-708* gene expression *versus* energy expenditure in all animals.

Figure 36 is a graphical representation of *AGT-708* gene expression *versus* change in carbohydrate oxidation in all animals.

Figure 37 is a graphical representation of *AGT-708* gene expression *versus* change in fat oxidation in all animals.

Figure 38 is a graphical representation of *AGT-708* gene expression *versus* food intake in exercise trained animals.

Figure 39 is a graphical representation of *AGT-708* gene expression *versus* change in fat oxidation in exercise trained animals.

- 18 -

**Figure 40** is a graphical representation of *AGT-708* gene expression *versus* change in carbohydrate oxidation in exercise trained animals.

**Figure 41** is a graphical representation of *AGT-708* gene expression in fasted animals. \*p =  
5 0.01.

**Figure 42** is a graphical representation of *AGT-708* gene expression *versus* blood glucose in fasted animals.

10 **Figure 43** is a graphical representation of *AGT-709* gene expression *versus* body weight in all animals.

**Figure 44** is a graphical representation of *AGT-709* gene expression *versus* energy expenditure in all animals.

15

**Figure 45** is a graphical representation of *AGT-709* gene expression *versus* body weight in exercise trained animals.

**Figure 46** is a graphical representation of *AGT-709* gene expression *versus* change in blood  
20 glucose in exercise trained animals.

**Figure 47** is a graphical representation of *AGT-709* gene expression *versus* change in body weight in exercise trained animals.

25 **Figure 48** is a graphical representation of *AGT-709* gene expression in fed animals.

**Figure 49** is a graphical representation of *AGT-709* gene expression *versus* body weight in fed animals.

-19 -

**Figure 50** is a graphical representation of *AGT-709* gene expression *versus* blood glucose in fed animals.

**Figure 51** is a graphical representation of *AGT-710* gene expression in *P. obesus* red gastrocnemius muscle after exercise. \*p = .0016.

**Figure 52** is a graphical representation of *AGT-710* gene expression *versus* energy expenditure in all animals.

**Figure 53** is a graphical representation of *AGT-710* gene expression *versus* blood glucose in all animals.

**Figure 54** is a graphical representation of *AGT-710* gene expression *versus* activity in all animals.

**Figure 55** is a graphical representation of *AGT-710* gene expression *versus* fat oxidation in exercise trained animals.

**Figure 56** is a graphical representation of *AGT-710* gene expression *versus* change in fat oxidation in exercise trained animals.

**Figure 57** is a graphical representation of *AGT-710* gene expression in fed animals. \*p = 0.021.

**Figure 58** is a graphical representation of *AGT-710* gene expression *versus* body weight in fed animals.

**Figure 59** is a graphical representation of *AGT-710* gene expression *versus* blood glucose in fed animals.

604-1767-011303

C:\Documents and Settings\Local Settings\Temp\2595715.mpeg-701.prowl.doc-01/1303

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is predicated in part on the identification of novel genes associated *inter alia* with regulation of obesity, anorexia, weight maintenance, diabetes and/or metabolic energy levels. The genes are identified following differential screening of mRNA from red gastrocnemius tissue in fed and fasted animals or in exercise trained and control *P. obesus* animals. The selection of gastrocnemius tissue is not intended to imply that differential expression does not occur in other tissue. The present invention further extends to homologs in other mammals and in particular humans as well as in other animals or organisms.

10

Accordingly, one aspect of the present invention provides a nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding an expression product or a derivative, homolog, analog or mimetic thereof wherein said nucleic acid molecule is differentially expressed in red gastrocnemius muscle tissue of *P. obesus* under fed and fasted or in exercise trained and control conditions or a homolog of said nucleic acid molecule.

15

The term "differentially expressed" is used in its most general sense and includes elevated levels of an expression product such as mRNA or protein or a secondary product such as cDNA in one tissue compared to another tissue or in the same tissue but under different conditions. Examples of different conditions includes differential expression in tissue from fed and fasted animals or in exercise trained and control animals. Differential expression is conveniently determined by a range of techniques including polymerase chain reaction (PCR) such as real-time PCR. Other techniques include suppression subtractive hybridization (SSH) and amplified fragment length polymorphism (AFLP) analysis. Microarray analysis of cDNA is particularly preferred.

20

25

A homolog refers to a genetic sequence in another animal or organism which has at least about 20% identity to the reference sequence. A preferred homolog is a human homolog.

Conveniently, an animal model may be employed to study the differences in gene expression in animal tissues under different conditions. In particular, the present invention is exemplified using the *P. obesus* (the Israeli Sand Rat) animal model of dietary-induced obesity and type 2 diabetes. In their natural desert habitat, an active lifestyle and saltbush diet ensure that they remain lean and normoglycemic (Shafir and Gutman, *J. Basic Clin. Physiol. Pharm.* 4: 83-99, 1993). However, in a laboratory setting on a diet of *ad libitum* chow (on which many other animal species remain healthy), a range of pathophysiological responses are seen (Barnett *et al.*, *Diabetologia* 37: 671-676, 1994a; Barnett *et al.*, *Int. J. Obesity* 18: 789-794, 1994b; Barnett *et al.*, *Diabete Nutr. Metab.* 8: 42-47, 1995). By the age of 16 weeks, more than half of the animals become obese and approximately one third develop type 2 diabetes. Only hyperphagic animals go on to develop hyperglycemia, highlighting the importance of excessive energy intake in the pathophysiology of obesity and type 2 diabetes in *P. obesus* (Collier *et al.*, *Ann. New York Acad. Sci.* 827: 50-63, 1997a; Walder *et al.*, *Obesity Res.* 5: 193-200, 1997a). Other phenotypes found include hyperinsulinemia, dyslipidemia and impaired glucose tolerance (Collier *et al.*, 1997; Collier *et al.*, *Exp. Clin. Endocrinol. Diabetes* 105: 36-37, 1997b). *P. obesus* exhibit a range of bodyweight and blood glucose and insulin levels which form a continuous curve that closely resembles the patterns found in human populations, including the inverted U-shaped relationship between blood glucose and insulin levels known as "Starling's curve of the pancreas" (Barnett *et al.*, 1994a). It is the heterogeneity of the phenotypic response of *P. obesus* which makes it an ideal model to study the etiology and pathophysiology of obesity and type 2 diabetes.

The animals are conveniently classified into three groups designated Groups A, B and C:

25

- Group A: animals are lean;
- Group B: animals are obese and non-diabetic; and
- Group C: animals are obese and diabetic.

- 23 -

In accordance with the present invention, a number of differentially expressed genetic sequences were identified in red gastrocnemius tissue in *P. obesus* under different feeding regimes (i.e. fed and fasted) or under exercise trained and control conditions. These genetic sequences have human and other animal homologs and, hence, the identification of these genetic sequences permits identification of genes involved in obesity, diabetes and energy balance.

Another aspect of the present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding or complementary to a sequence encoding an expression product or a derivative, homolog, analog or mimetic thereof wherein said nucleotide sequence is as substantially set forth in SEQ ID NO:1 (AGT-701) or SEQ ID NO:2 (AGT-702) or SEQ ID NO:3 (AGT-704) or SEQ ID NO:4 (AGT-705) or SEQ ID NO:5 (AGT-706) or SEQ ID NO:6 (AGT-707) or SEQ ID NO:7 (AGT-708) or SEQ ID NO:8 (AGT-709) or SEQ ID NO:9 (AGT-710) or a nucleotide sequence having at least about 30% similarity to all or part of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 and/or is capable of hybridizing to one or more of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 or their complementary forms under low stringency conditions at 42°C and wherein said nucleic acid molecule is differentially expressed in red gastrocnemius muscle tissue under fed or fasted or in exercise trained and control conditions.

Higher similarities are also contemplated by the present invention such as greater than about 40% or 50% or 60% or 70% or 80% or 90% or 95% or 96% or 97% or 98% or 99% or above.

An expression product includes an RNA molecule such as an mRNA transcript as well as a protein. Some genes are non-protein encoding genes and produce mRNA or other RNA molecules and are involved in regulation by RNA:DNA, RNA:RNA or RNA:protein interaction. The RNA (e.g. mRNA) may act directly or *via* the induction of other molecules

- 24 -

such as RNAi or *via* products mediated from splicing events (e.g. exons or introns). Other genes encode mRNA transcripts which are then translated into proteins. A protein includes a polypeptide. The differentially expressed nucleic acid molecules, therefore, may encode mRNAs only or, in addition, proteins. Both mRNAs and proteins are forms of "expression products".

Reference herein to similarity is generally at a level of comparison of at least 15 consecutive or substantially consecutive nucleotides. It is particularly convenient, however, to determine similarity by comparing a total or complete sequence, after optimal alignment.

10

The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which may encode different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. In a particularly preferred embodiment, nucleotide sequence comparisons are made at the level of identity rather than similarity.

Terms used to describe sequence relationships between two or more polynucleotides include "reference sequence", "comparison window", "sequence similarity", "sequence identity", "percentage of sequence similarity", "percentage of sequence identity", "substantially similar" and "substantial identity". A "reference sequence" is at least 12 but frequently 15 to 18 and often at least 25 or above, such as 30 monomer units in length. Because two polynucleotides may each comprise (1) a sequence (i.e. only a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window" refers to a conceptual segment of typically 12 contiguous residues that is compared to a reference sequence. The comparison window may comprise additions or

- 25 -

deletions (i.e. gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by computerized implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin  
5 Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e. resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also may be made to the BLAST family of programs as for example disclosed by Altschul *et al.* (*Nucl. Acids Res.* 25: 3389, 1997). A detailed discussion of  
10 sequence analysis can be found in Unit 19.3 of Ausubel *et al.* ("Current Protocols in Molecular Biology" John Wiley & Sons Inc, Chapter 15, 1994-1998). A range of other algorithms may be used to compare the nucleotide and amino acid sequences such as but not limited to PILEUP, CLUSTALW, SEQUENCHER or VectorNTI.

15 The terms "sequence similarity" and "sequence identity" as used herein refers to the extent that sequences are identical or functionally or structurally similar on a nucleotide-by-nucleotide basis over a window of comparison. Thus, a "percentage of sequence identity", for example, is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g.  
20 A, T, C, G, I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. For the purposes of the present invention, "sequence identity" will be understood to mean the "match percentage" calculated by the DNASIS computer program (Version 2.5 for  
25 windows; available from Hitachi Software engineering Co., Ltd., South San Francisco, California, USA) using standard defaults as used in the reference manual accompanying the software. Similar comments apply in relation to sequence similarity.

- 26 -

Reference herein to a low stringency includes and encompasses from at least about 0 to at least about 15% v/v formamide and from at least about 1 M to at least about 2 M salt for hybridization, and at least about 1 M to at least about 2 M salt for washing conditions. Generally, low stringency is at from about 25-30°C to about 42°C. The temperature may be  
 5 altered and higher temperatures used to replace formamide and/or to give alternative stringency conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5 M to at least about 0.9 M salt for hybridization, and at least about 0.5 M to at least about 0.9 M salt for washing conditions, or  
 10 high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01 M to at least about 0.15 M salt for hybridization, and at least about 0.01 M to at least about 0.15 M salt for washing conditions. In general, washing is carried out  $T_m = 69.3 + 0.41 (G+C)\%$  (Marmur and Doty, *J. Mol. Biol.* 5: 109, 1962). However, the  $T_m$  of a duplex DNA decreases by 1°C with every increase of 1%  
 15 in the number of mismatch base pairs (Bonner and Laskey, *Eur. J. Biochem.* 46: 83, 1974). Formamide is optional in these hybridization conditions. Accordingly, particularly preferred levels of stringency are defined as follows: low stringency is 6 x SSC buffer, 0.1% w/v SDS at 25-42°C; a moderate stringency is 2 x SSC buffer, 0.1% w/v SDS at a temperature in the range 20°C to 65°C; high stringency is 0.1 x SSC buffer, 0.1% w/v SDS at a temperature of at least  
 20 65°C.

The nucleotide sequence or amino acid sequence of the present invention may correspond to exactly the same sequence of the naturally occurring gene (or corresponding cDNA) or protein or other expression product or may carry one or more nucleotide or amino acid substitutions,  
 25 additions and/or deletions. The nucleotide sequences set forth in SEQ ID NO:1 (AGT-701), SEQ ID NO:2 (AGT-702) and SEQ ID NO:3 (AGT-704) or SEQ ID NO:4 (AGT-705) or SEQ ID NO:5 (AGT-706) or SEQ ID NO:6 (AGT-707) or SEQ ID NO:7 (AGT-708) or SEQ ID NO:8 (AGT-709) or SEQ ID NO:9 (AGT-710) correspond to novel genes referred to in parenthesis. The corresponding expression products are AGT-701, AGT-702, AGT-704,

- 27 -

AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710. Reference herein to *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and *AGT-710* includes, where appropriate, reference to the genomic gene or cDNA as well as any naturally occurring or induced derivatives. Apart from the substitutions, deletions and/or  
5 additions to the nucleotide sequence, the present invention further encompasses mutants, fragments, parts and portions of the nucleotide sequence corresponding to *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and *AGT-710*.

Another aspect of the present invention provides a nucleic acid molecule or derivative,  
10 homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:1 (*AGT-701*) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:1 or a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or its complementary  
15 form under low stringency conditions.

Yet another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said  
20 nucleotide sequence is substantially as set forth in SEQ ID NO:2 (*AGT-702*) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:2 or a nucleotide sequence capable of hybridizing to SEQ ID NO:2 or its complementary form under low stringency conditions.

25 Still yet another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:3 (*AGT-704*) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID

- 28 -

NO:3 or a nucleotide sequence capable of hybridizing to SEQ ID NO:3 or their complementary forms under low stringency conditions.

Even yet another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a  
5 nucleotide sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:4 (AGT-705) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:4 or a nucleotide sequence capable of hybridizing to SEQ ID NO:4 or its  
10 complementary form under low stringency conditions.

Even still another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein  
15 said nucleotide sequence is substantially as set forth in SEQ ID NO:5 (AGT-706) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:5 or a nucleotide sequence capable of hybridizing to SEQ ID NO:5 or its complementary form under low stringency conditions.

20 Another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:6 (AGT-707) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID  
25 NO:6 or a nucleotide sequence capable of hybridizing to SEQ ID NO:6 or its complementary form under low stringency conditions.

A further aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide

- 29 -

sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:7 (AGT-708) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:7 or a nucleotide sequence capable of hybridizing to SEQ ID NO:7 or its complementary  
5 form under low stringency conditions.

Yet another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said  
10 nucleotide sequence is substantially as set forth in SEQ ID NO:8 (AGT-709) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:8 or a nucleotide sequence capable of hybridizing to SEQ ID NO:8 or its complementary form under low stringency conditions.

15 Still another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:9 (AGT-710) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID  
20 NO:9 or a nucleotide sequence capable of hybridizing to SEQ ID NO:9 or its complementary form under low stringency conditions.

The expression pattern of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 has been determined, *inter alia*, to indicate an involvement  
25 in the regulation of one or more of obesity, anorexia, weight maintenance, diabetes and/or energy metabolism. In addition to the differential expression of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 in red gastrocnemius muscle of fed *versus* fasted or exercise trained *versus* control animals, these genes may also be expressed in other tissues including but in no way limited to brain, muscle, adipose tissue,

pancreas and gastrointestinal tract. The nucleic acid molecule corresponding to each of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* or *AGT-710* is preferably a DNA such as a cDNA sequence or a genomic DNA. A genomic sequence may also comprise exons and introns. A genomic sequence may also include a promoter region or other regulatory regions.

A homolog is considered to be a gene from another animal species which has the same or greater than 30% similarity to one of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* and/or which has a similar function. The above-mentioned genes are exemplified herein from *P. obesus* red gastrocnemius muscle. The present invention extends, however, to the homologous gene, as determined by nucleotide sequence and/or function, from humans, primates, livestock animals (e.g. cows, sheep, pigs, horses, donkeys), laboratory test animals (e.g. mice, guinea pigs, hamsters, rabbits), companion animals (e.g. cats, dogs) and captured wild animals (e.g. rodents, foxes, deer, kangaroos). Homologs may also be present in microorganisms and *C. elegans*.

The nucleic acids of the present invention and in particular *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* and their derivatives and homologs may be in isolated or purified form and/or may be ligated to a vector such as an expression vector. Expression may be in a eukaryotic cell line (e.g. mammalian, insect or yeast cells) or in prokaryote cells (e.g. *E. coli*) or in both. By "isolated" is meant a nucleic acid molecule having undergone at least one purification step and this is conveniently defined, for example, by a composition comprising at least about 10% subject nucleic acid molecule, preferably at least about 20%, more preferably at least about 30%, still more preferably at least about 40-50%, even still more preferably at least about 60-70%, yet even still more preferably 80-90% or greater of subject nucleic acid molecule relative to other components as determined by molecular weight, encoding activity, nucleotide sequence, base composition or other convenient means. The nucleic acid molecule of the present invention may also be considered, in a preferred embodiment, to be biologically pure. The nucleic acid molecule may be ligated

- 31 -

to an expression vector capable of expression in a prokaryotic cell (e.g. *E. coli*) or a eukaryotic cell (e.g. yeast cells, fungal cells, insect cells, mammalian cells or plant cells). The nucleic acid molecule may be ligated or fused or otherwise associated with a nucleic acid molecule encoding another entity such as, for example, a signal peptide. It may also comprise additional  
5 nucleotide sequence information fused, linked or otherwise associated with it either at the 3' or 5' terminal portions or at both the 3' and 5' terminal portions. The nucleic acid molecule may also be part of a vector, such as an expression vector.

The derivatives of the nucleic acid molecule of the present invention include oligonucleotides,  
10 PCR primers, antisense molecules, molecules suitable for use in co-suppression and fusion nucleic acid molecules. Ribozymes and DNazymes are also contemplated by the present invention directed to *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* or their mRNAs. Derivatives and homologs of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* are conveniently  
15 encompassed by those nucleotide sequences capable of hybridizing to one or more of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 or their complementary forms under low stringency conditions.

20 Derivatives include fragments, parts, portions, mutants, variants and mimetics from natural, synthetic or recombinant sources including fusion nucleic acid molecules. Derivatives may be derived from insertion, deletion or substitution of nucleotides.

Another aspect of the present invention provides an isolated expression product or a  
25 derivative, homolog, analog or mimetic thereof which is produced in larger or lesser amounts in red gastrocnemius muscle in obese animals compared to lean animals or in fed (including re-fed) compared to fasted animals or in animals under exercise trained compared to control conditions.

- 32 -

An expression product, as indicated above, may be RNA or protein. Insofar as the product is a protein, derivatives include amino acid insertional derivatives such as amino and/or carboxylic terminal fusions as well as intra-sequence insertions of single or multiple amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in a protein although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterized by the removal of one or more amino acids from the sequence. Substitutional amino acid variants are those in which at least one residue in the sequence has been removed and a different residue inserted in its place. An example of substitutional amino acid variants are conservative amino acid substitutions. Conservative amino acid substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine. Additions to amino acid sequences include fusions with other peptides, polypeptides or proteins.

15

Chemical and functional equivalents of protein forms of the expression products AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 or AGT-710 should be understood as molecules exhibiting any one or more of the functional activities of these molecules and may be derived from any source such as being chemically synthesized or identified *via* screening processes such as natural product screening or screening of chemical libraries.

20

The derivatives include fragments having particular epitopes or parts of the entire protein fused to peptides, polypeptides or other proteinaceous or non-proteinaceous molecules.

25

Reference herein to AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 or AGT-710 includes reference to isolated or purified naturally occurring AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 or AGT-710 as well as any derivatives, homologs, analogs and mimetics thereof. Derivatives

- 33 -

include parts, fragments and portions of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 or AGT-710 as well as single and multiple amino acid substitutions, deletions and/or additions to AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 when the expression products are proteins.

- 5 A derivative of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 or AGT-710 is conveniently encompassed by molecules encoded by a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 under low stringency conditions.

10

Other derivatives of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 include chemical analogs. Analogs of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 contemplated herein include, but are not limited to, modifications to side chains, incorporation of unnatural

15 amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogs.

- Examples of side chain modifications contemplated by the present invention include
- 20 modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with  $\text{NaBH}_4$ ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulfonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-
- 25 phosphate followed by reduction with  $\text{NaBH}_4$ .

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

- 34 -

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitization, for example, to a corresponding amide.

5 Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

10 Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

15 Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

20 Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 4.

**TABLE 4**  
***Codes for non-conventional amino acids***

5	Non-conventional amino acid	Code	Non-conventional amino acid	Code
	$\alpha$ -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	$\alpha$ -amino- $\alpha$ -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
10	aminocyclopropane-carboxylate	Cpro	L-N-methylasparagine	Nmasn
	aminoisobutyric acid	Aib	L-N-methylaspartic acid	Nmasp
	aminonorbomyl-carboxylate	Norb	L-N-methylcysteine	Nmcys
			L-N-methylglutamine	Nmgln
			L-N-methylglutamic acid	Nmglu
15	cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Das	L-N-methylmethionine	Nmmet
20	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
25	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
30	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug

- 36 -

	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva
	D-tyrosine	Dtyr	$\alpha$ -methyl-aminoisobutyrate	Maib
	D-valine	Dval	$\alpha$ -methyl- $\gamma$ -aminobutyrate	Mgabv
5	D- $\alpha$ -methylalanine	Dmala	$\alpha$ -methylcyclohexylalanine	Mchexa
	D- $\alpha$ -methylarginine	Dmarg	$\alpha$ -methylcyclopentylalanine	Mcpen
	D- $\alpha$ -methylasparagine	Dmasn	$\alpha$ -methyl- $\alpha$ -naphthylalanine	Manap
	D- $\alpha$ -methylaspartate	Dmasp	$\alpha$ -methylpenicillamine	Mpen
	D- $\alpha$ -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
10	D- $\alpha$ -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- $\alpha$ -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- $\alpha$ -methylisoleucine	Dmile	N-amino- $\alpha$ -methylbutyrate	Nmaabu
	D- $\alpha$ -methylleucine	Dmleu	$\alpha$ -naphthylalanine	Anap
	D- $\alpha$ -methyllysine	Dmlys	N-benzylglycine	Nphe
15	D- $\alpha$ -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- $\alpha$ -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- $\alpha$ -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- $\alpha$ -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- $\alpha$ -methylserine	Dmser	N-cyclobutylglycine	Ncbut
20	D- $\alpha$ -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- $\alpha$ -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- $\alpha$ -methyltyrosine	Dmtty	N-cyclodecylglycine	Ncdec
	D- $\alpha$ -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
25	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
30	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr

- 37 -

	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
	D-N-methylleucine	Dnmleu	N-(3-indolylethyl)glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- $\gamma$ -aminobutyrate	Nmgabu
5	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmt
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpn
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
10	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- $\alpha$ -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	$\gamma$ -aminobutyric acid	Gabu	N-( <i>p</i> -hydroxyphenyl)glycine	Nhtyr
15	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- $\alpha$ -methylalanine	Mala
	L- $\alpha$ -methylarginine	Marg	L- $\alpha$ -methylasparagine	Masn
	L- $\alpha$ -methylaspartate	Masp	L- $\alpha$ -methyl- <i>t</i> -butylglycine	Mtbug
20	L- $\alpha$ -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- $\alpha$ -methylglutamine	Mgln	L- $\alpha$ -methylglutamate	Mglu
	L- $\alpha$ -methylhistidine	Mhis	L- $\alpha$ -methylhomophenylalanine	Mhphe
	L- $\alpha$ -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- $\alpha$ -methylleucine	Mleu	L- $\alpha$ -methyllysine	Mlys
25	L- $\alpha$ -methylmethionine	Mmet	L- $\alpha$ -methylnorleucine	Mnle
	L- $\alpha$ -methylnorvaline	Mnva	L- $\alpha$ -methylornithine	Morn
	L- $\alpha$ -methylphenylalanine	Mphe	L- $\alpha$ -methylproline	Mpro
	L- $\alpha$ -methylserine	Mser	L- $\alpha$ -methylthreonine	Mthr
	L- $\alpha$ -methyltryptophan	Mtrp	L- $\alpha$ -methyltyrosine	Mtyr
30	L- $\alpha$ -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe

- 38 -

N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
carbamylmethyl)glycine		carbamylmethyl)glycine	
1-carboxy-1-(2,2-diphenyl-	Nmbc		
ethylamino)cyclopropane			

5

Crosslinkers can be used, for example, to stabilize 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having (CH<sub>2</sub>)<sub>n</sub> spacer groups with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional  
10 reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C<sub>α</sub> and N<sub>α</sub>-methylamino acids; introduction of double bonds between C<sub>α</sub> and C<sub>β</sub> atoms of amino acids and the formation of cyclic peptides or analogs  
15 by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

All such modifications may also be useful in stabilizing the AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 molecule for  
20 use in *in vivo* administration protocols or for diagnostic purposes.

As stated above, the expression product may be a RNA or protein.

The term "protein" should be understood to encompass peptides, polypeptides and  
25 proteins. The protein may be glycosylated or unglycosylated and/or may contain a range of other molecules fused, linked, bound or otherwise associated to the protein such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins. Reference hereinafter to a "protein" includes a protein comprising a sequence of amino acids as well as a protein associated with other molecules such as amino acids, lipids, carbohydrates or  
30 other peptides, polypeptides or proteins.

- 39 -

In a particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:1 or a derivative, homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:1 or a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or its complementary form under low stringency conditions.

In another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:2 or a derivative, homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:2 or a nucleotide sequence capable of hybridizing to SEQ ID NO:2 or its complementary form under low stringency conditions.

In still another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:3 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:3 or a nucleotide sequence capable of hybridizing to SEQ ID NO:3 or their complementary form under low stringency conditions.

In yet another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:4 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:4 or a nucleotide sequence capable of hybridizing to SEQ ID NO:4 or their complementary form under low stringency conditions.

In another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:5 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:5 or a nucleotide sequence capable of hybridizing to SEQ ID NO:5 or its complementary form under low stringency conditions.

- 40 -

In still another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:6 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:6 or a nucleotide sequence capable of hybridizing to SEQ ID NO:6 or its  
5 complementary form under low stringency conditions.

In a further particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:7 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID  
10 NO:7 or a nucleotide sequence capable of hybridizing to SEQ ID NO:7 or its complementary form under low stringency conditions.

In still yet another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:8 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID  
15 NO:8 or a nucleotide sequence capable of hybridizing to SEQ ID NO:8 or its complementary form under low stringency conditions.

In yet another particularly preferred embodiment, the expression product is encoded by a  
20 sequence of nucleotides comprising SEQ ID NO:9 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:9 or a nucleotide sequence capable of hybridizing to SEQ ID NO:9 or its complementary form under low stringency conditions.

25 Higher similarities are also contemplated by the present invention such as greater than 40% or 50% or 60% or 70% or 80% or 90% or 95% or 96% or 97% or 98% or 99% or above.

Another aspect of the present invention is directed to an isolated expression product selected from the list consisting of:-

- 41 -

- (i) an mRNA or protein encoded by a novel nucleic acid molecule which molecule is differentially expressed in red gastrocnemius muscle from *P. obesus* animals under fed or fasting conditions or in exercise trained and control animals or a derivative, homolog, analog, chemical equivalent or mimetic thereof;
- 5 (ii) an mRNA or protein encoded by a novel nucleic acid molecule which molecule is differentially expressed in red gastrocnemius muscle from *P. obesus* animals under fed or fasting conditions or in exercise trained and control animals or a derivative, homolog, analog, chemical equivalent or mimetic thereof;
- 10 (iii) AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 or AGT-710 or a derivative, homolog, analog, chemical equivalent or mimetic thereof;
- 15 (iv) a protein encoded by a nucleotide sequence comprising SEQ ID NO:1 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 20 (vi) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:2 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 25 (vii) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:3 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to these sequences or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 30 (viii) a protein comprising an amino acid sequence substantially as set forth in SEQ ID NO:4 or a derivative, homolog or analog thereof or a sequence encoding an amino

acid sequence having at least about 30% similarity to these sequences or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;

- 5 (ix) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:5 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 10 (x) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:6 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 15 (xi) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:7 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 20 (xii) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:8 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 25 (xiii) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:9 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 30 (xiv) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide sequence comprising SEQ ID NO:1 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions;

- 43 -

- 5
- (xv) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide sequence comprising SEQ ID NO:2 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions;
- (xvi) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide sequence comprising SEQ ID NO:3 or their complementary forms or a derivative, homolog or analog thereof under low stringency conditions;
- 10 (xvii) protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide sequence comprising SEQ ID NO:4 or their complementary forms or a derivative, homolog or analog thereof under low stringency conditions;
- 15 (xviii) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide sequence comprising SEQ ID NO:5 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions;
- 20 (xix) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide sequence comprising SEQ ID NO:6 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions;
- 25 (xx) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide sequence comprising SEQ ID NO:7 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions;
- (xxi) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide sequence comprising SEQ ID NO:8 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions; and

(xxii) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide sequence comprising SEQ ID NO:9 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions.

- 5 The protein of the present invention is preferably in isolated form. By "isolated" is meant a protein having undergone at least one purification step and this is conveniently defined, for example, by a composition comprising at least about 10% subject protein, preferably at least about 20%, more preferably at least about 30%, still more preferably at least about 40-50%, even still more preferably at least about 60-70%, yet even still more preferably
- 10 80-90% or greater of subject protein relative to other components as determined by molecular weight, amino acid sequence or other convenient means. The protein of the present invention may also be considered, in a preferred embodiment, to be biologically pure.
- 15 Without limiting the theory or mode of action of the present invention, the expression of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and *AGT-710* is thought to relate to regulation of body weight and glucose homeostasis. Modulation of expression of these genes is thought *inter alia* to regulate energy balance *via* effects on energy intake and also effects on carbohydrate/fat metabolism. The energy
- 20 intake effects are likely to be mediated *via* the central nervous system but peripheral effects on the metabolism of both carbohydrate and fat are possible. The expression of these genes may also be regulated by fasting and feeding. Accordingly, regulating the expression and/or activity of these genes or their expression products provides a mechanism for regulating both body weight and energy metabolism, including
- 25 carbohydrate and fat metabolism.

The identification of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and *AGT-710* permits the generation of a range of therapeutic molecules capable of modulating expression of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706,*

30 *AGT-707, AGT-708, AGT-709* and *AGT-710* or modulating the activity of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and *AGT-710*.

- 45 -

Modulators contemplated by the present invention include agonists and antagonists of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* expression. Antagonists of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* expression include antisense molecules, ribozymes and co-suppression molecules (including any molecules which induce RNAi). Agonists include molecules which increase promoter activity or which interfere with negative regulatory mechanisms. Antagonists of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* include antibodies and inhibitor peptide fragments. All such molecules may first need to be modified to enable such molecules to penetrate cell membranes. Alternatively, viral agents may be employed to introduce genetic elements to modulate expression of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710*. In so far as *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* act in association with other genes such as the *ob* gene which encodes leptin, the therapeutic molecules may target *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* and *ob* genes or their translation products.

The present invention contemplates, therefore, a method for modulating expression of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* in a mammal, said method comprising contacting the *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* gene with an effective amount of a modulator of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* expression for a time and under conditions sufficient to up-regulate or down-regulate or otherwise modulate expression of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710*.

For example, a nucleic acid molecule encoding *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* or a derivative or homolog thereof may be introduced into a cell to enhance the ability of that cell to produce *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710*, conversely, *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-*

709 and AGT-710 sense and/or antisense sequences such as oligonucleotides may be introduced to decrease expression of the genes at the level of transcription, post-transcription or translation. Sense sequences preferably encode hair pin RNA molecules or double-stranded RNA molecules.

5

Another aspect of the present invention contemplates a method of modulating activity of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 in a mammal, said method comprising administering to said mammal a modulating effective amount of a molecule for a time and under conditions sufficient to  
10 increase or decrease AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 activity. The molecule may be a proteinaceous molecule or a chemical entity and may also be a derivative of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 or its ligand.

15 Modulating levels of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 expression or AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and/or AGT-710 activity or function is important in the treatment of a range of conditions such as obesity, anorexia, energy imbalance, diabetes, metabolic syndrome, dyslipidemia, hypertension and insulin  
20 resistance. It may also be useful in the agricultural industry to assist in the generation of leaner animals, or where required, more obese animals. Accordingly, mammals contemplated by the present invention include but are not limited to humans, primates, livestock animals (e.g. pigs, sheep, cows, horses, donkeys), laboratory test animals (e.g. mice, rats, guinea pigs, hamsters, rabbits), companion animals (e.g. dogs, cats) and  
25 captured wild animals (e.g. foxes, kangaroos, deer). A particularly preferred host is a human, primate or livestock animal.

Accordingly, the present invention contemplates therapeutic and prophylactic use of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and/or  
30 AGT-710 expression products or AGT-701, AGT-702, AGT-704, AGT-705, AGT-706,

- 47 -

*AGT-707, AGT-708, AGT-709 and AGT-710* genetic mutants and/or agonists or antagonists agents thereof.

The present invention contemplates, therefore, a method of modulating expression of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and/or *AGT-710* in a mammal, said method comprising contacting the *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and/or *AGT-710* genes with an effective amount of an agent for a time and under conditions sufficient to up-regulate, down-regulate or otherwise module expression of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and *AGT-710*.

Another aspect of the present invention contemplates a method of modulating activity of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and/or *AGT-710* in a subject, said method comprising administering to said subject a modulating effective amount of an agent for a time and under conditions sufficient to increase or decrease *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and/or *AGT-710* activity or function.

Modulation of activity by the administration of an agent to a mammal can be achieved by one of several techniques, including, but in no way limited to, introducing into a mammal a proteinaceous or non-proteinaceous molecule which:

- (i) modulates expression of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and/or *AGT-710*;
- (ii) functions as an antagonist of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and/or *AGT-710*; and/or
- (iii) functions as an agonist of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and/or *AGT-710*.

- 48 -

The molecules which may be administered to a mammal in accordance with the present invention may also be linked to a targeting means such as a monoclonal antibody, which provides specific delivery of these molecules to the target cells.

- 5 A further aspect of the present invention relates to the use of the invention in relation to mammalian disease conditions. For example, the present invention is particularly useful in a therapeutic or prophylactic treatment of obesity, anorexia, diabetes or energy imbalance.

- Accordingly, another aspect of the present invention relates to a method of treating a  
10 mammal suffering from a condition characterized by one or more symptoms of obesity, anorexia, diabetes and/or energy imbalance, said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710* or sufficient to modulate the activity of *AGT-701*,  
15 *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710*.

- In another aspect, the present invention relates to a method of treating a mammal suffering from a disease condition characterized by one or more symptoms of obesity, anorexia,  
20 diabetes or energy imbalance, said method comprising administering to said mammal an effective amount of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710* or *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710*.

- 25 An agent includes proteinaceous or non-proteinaceous molecules such as antibodies, natural products, chemical entities or nucleic acid molecules (including antisense molecules, sense molecules, ribozymes, ds-RNA molecules or DNA-targeting molecules).

- An "effective amount" means an amount necessary at least partly to attain the desired  
30 immune response (e.g. against *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*,

- 49 -

AGT-707, AGT-708, AGT-709 or AGT-710) or to delay the onset or inhibit progression or halt altogether the onset or progression of a particular condition.

In accordance with these methods, AGT-701, AGT-702, AGT-704, AGT-705, AGT-706,  
5 AGT-707, AGT-708, AGT-709 and/or AGT-710 or *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and/or *AGT-710* or agents capable of modulating the expression or activity of said molecules may be co-administered with one or more other compounds or other molecules. By "co-administered" is meant simultaneous administration in the same formulation or in two different formulations *via* the same or  
10 different routes or sequential administration by the same or different routes. By "sequential" administration is meant a time difference of from seconds, minutes, hours or days between the administration of the two types of molecules. These molecules may be administered in any order.

15 In yet another aspect, the present invention relates to the use of an agent capable of modulating the expression of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and/or *AGT-710* or a derivative, homolog or analog thereof in the manufacture of a medicament for the treatment of a condition characterized by obesity, anorexia, weight maintenance, diabetes and/or energy imbalance.

20

In still yet another aspect, the present invention relates to the use of an agent capable of modulating the activity of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and/or AGT-710 or a derivative, homolog, analog, chemical equivalent or mimetic thereof in the manufacture of a medicament for the treatment of a  
25 condition characterized by obesity, anorexia, weight maintenance, diabetes and/or energy imbalance.

A further aspect of the present invention relates to the use of *AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709* and/or *AGT-710* or derivative,  
30 homolog or analog thereof or AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and/or AGT-710 or derivative, homolog, analog, chemical

- 50 -

equivalent or mimetic thereof in the manufacture of a medicament for the treatment of a condition characterized by obesity, anorexia, weight maintenance, diabetes and/or energy imbalance.

- 5 Still yet another aspect of the present invention relates to agents for use in modulating the expression of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710* or a derivative, homolog or analog thereof.

- A further aspect relates to agents for use in modulating *AGT-701*, *AGT-702*, *AGT-704*,  
10 *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710* activity or a derivative, homolog, analog, chemical equivalent or mimetic thereof.

- Still another aspect of the present invention relates to *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710* or derivative, homolog or  
15 analog thereof or *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and/or *AGT-710* or derivative, homolog, analog, chemical equivalent or mimetic thereof for use in treating a condition characterized by one or more symptoms of obesity, anorexia, weight maintenance, diabetes and/or energy imbalance.

- 20 In a related aspect of the present invention, the mammal undergoing treatment may be a human or an animal in need of therapeutic or prophylactic treatment.

- Accordingly, the present invention contemplates in one embodiment a composition comprising a modulator of *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*,  
25 *AGT-708*, *AGT-709* and *AGT-710* expression or *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* activity and one or more pharmaceutically acceptable carriers and/or diluents. In another embodiment, the composition comprises *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* or a derivative, homolog, analog or mimetic thereof  
30 and one or more pharmaceutically acceptable carriers and/or diluents. The compositions may also comprise leptin or modulations of leptin activity or *ob* expression.

- 51 -

For brevity, all such components of such a composition are referred to as "active components".

- 5 The compositions of active components in a form suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of
- 10 microorganisms such as bacteria and fungi.

The carrier can be a solvent or other medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.

15

- The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable
- 20 compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

- Sterile injectable solutions are prepared by incorporating the active components in the required amount in the appropriate solvent with optionally other ingredients, as required,
- 25 followed by sterilization by, for example, filter sterilization, irradiation or other convenient means. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

30

- 52 -

When AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 or AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 are suitably protected, they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed  
5 in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active  
10 compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1  
15  $\mu$ g and 2000 mg of active compound.

The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the  
20 like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For  
25 instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active  
30 compound may be incorporated into sustained-release preparations and formulations.

- 53 -

Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

- It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.
- The principal active component may be compounded for convenient and effective administration in sufficient amounts with a suitable pharmaceutically acceptable carrier in dosage unit form. A unit dosage form can, for example, contain the principal active component in amounts ranging from 0.5  $\mu$ g to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.5  $\mu$ g to about 2000 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

In general terms, effective amounts of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 or AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 will range from 0.01

- 54 -

ng/kg/body weight to above 10,000 mg/kg/body weight. Alternative amounts range from 0.1 ng/kg/body weight to above 1000 mg/kg/body weight. The active ingredients may be administered per minute, hour, day, week, month or year depending on the condition being treated. The route of administration may vary and includes intravenous, intraperitoneal, sub-cutaneous, intramuscular, intranasal, *via* suppository, *via* infusion, *via* drip, orally or *via* other convenient means.

The pharmaceutical composition may also comprise genetic molecules such as a vector capable of transfecting target cells where the vector carries a nucleic acid molecule capable of modulating AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 expression or AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 activity. The vector may, for example, be a viral vector.

Still another aspect of the present invention is directed to antibodies to AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 and their derivatives and homologs insofar as AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 are proteins. Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 or may be specifically raised to AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 or derivatives or homologs thereof. In the case of the latter, AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 or their derivatives or homologs may first need to be associated with a carrier molecule. The antibodies and/or recombinant AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 or their derivatives of the present invention are particularly useful as therapeutic or diagnostic agents. An antibody "to" a molecule includes an antibody specific for said molecule.

- 55 -

AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 and their derivatives can be used to screen for naturally occurring antibodies to AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 which may occur in certain autoimmune diseases. Alternatively, specific  
5 antibodies can be used to screen for AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710. Techniques for such assays are well known in the art and include, for example, sandwich assays and ELISA.

Antibodies to AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708,  
10 AGT-709 and AGT-710 of the present invention may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to the *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* or may be specifically raised to these gene products. In the case of the latter, the AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 protein may need first  
15 to be associated with a carrier molecule. Alternatively, fragments of antibodies may be used such as Fab fragments. Furthermore, the present invention extends to recombinant and synthetic antibodies and to antibody hybrids. A "synthetic antibody" is considered herein to include fragments and hybrids of antibodies. The antibodies of this aspect of the present invention are particularly useful for immunotherapy and may also be used as a  
20 diagnostic tool or as a means for purifying AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710.

For example, specific antibodies can be used to screen for AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 proteins. The latter  
25 would be important, for example, as a means for screening for levels of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 in a cell extract or other biological fluid or purifying AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 made by recombinant means from culture supernatant fluid. Techniques for the assays contemplated herein are known  
30 in the art and include, for example, sandwich assays and ELISA.

- 56 -

It is within the scope of this invention to include any second antibodies (monoclonal, polyclonal or fragments of antibodies) directed to the first mentioned antibodies discussed above. Both the first and second antibodies may be used in detection assays or a first antibody may be used with a commercially available anti-immunoglobulin antibody. An  
5 antibody as contemplated herein includes any antibody specific to any region of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504.

Both polyclonal and monoclonal antibodies are obtainable by immunization with the enzyme or protein and either type is utilizable for immunoassays. The methods of  
10 obtaining both types of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504, or antigenic parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoabsorbent techniques. Although antibodies  
15 produced by this method are utilizable in virtually any type of immunoassay, they are generally less favoured because of the potential heterogeneity of the product.

The use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product. The  
20 preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art. (See, for example, Douillard and Hoffman, Basic Facts about Hybridomas, in *Compendium of Immunology* Vol. II, ed. by Schwartz, 1981; Kohler and Milstein, *Nature* 256: 495-499,  
25 1975; Kohler and Milstein, *European Journal of Immunology* 6: 511-519, 1976.)

Another aspect of the present invention contemplates a method for detecting AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 or a derivative or homolog thereof in a biological sample from a subject, said method  
30 comprising contacting said biological sample with an antibody specific for AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710

- 57 -

or their antigenic derivatives or homologs for a time and under conditions sufficient for a complex to form, and then detecting said complex.

The presence of the complex is indicative of the presence of AGT-701, AGT-702, AGT-  
5 704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710. This assay may  
be quantitated or semi-quantitated to determine a propensity to develop obesity or other  
conditions or to monitor a therapeutic regimen.

The presence of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-  
10 708, AGT-709 and AGT-710 may be accomplished in a number of ways such as by  
Western blotting and ELISA procedures. A wide range of immunoassay techniques are  
available as can be seen by reference to U.S. Patent Nos. 4,016,043, 4,424,279 and  
4,018,653. These, of course, include both single-site and two-site or "sandwich" assays of  
the non-competitive types, as well as in the traditional competitive binding assays. These  
15 assays also include direct binding of a labelled antibody to a target.

Sandwich assays are among the most useful and commonly used assays. A number of  
variations of the sandwich assay technique exist, and all are intended to be encompassed  
by the present invention. Briefly, in a typical forward assay, an unlabelled antibody is  
20 immobilized on a solid substrate and the sample to be tested brought into contact with the  
bound molecule. After a suitable period of incubation, for a period of time sufficient to  
allow formation of an antibody-AGT-701, AGT-702, AGT-704, AGT-705, AGT-706,  
AGT-707, AGT-708, AGT-709 and AGT-710 complex, a second antibody specific to the  
AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and  
25 AGT-710, labeled with a reporter molecule capable of producing a detectable signal, is  
then added and incubated, allowing time sufficient for the formation of another complex of  
antibody-AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708,  
AGT-709 and AGT-710-labeled antibody. Any unreacted material is washed away, and the  
presence of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708,  
30 AGT-709 and AGT-710 is determined by observation of a signal produced by the reporter  
molecule. The results may either be qualitative, by simple observation of the visible signal,

- 58 -

or may be quantitated by comparing with a control sample containing known amounts of hapten. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will  
5 be readily apparent. In accordance with the present invention, the sample is one which might contain AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710 including cell extract, tissue biopsy or possibly serum, saliva, mucosal secretions, lymph, tissue fluid and respiratory fluid. The sample is, therefore, generally a biological sample comprising biological fluid but also extends to fermentation  
10 fluid and supernatant fluid such as from a cell culture.

The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs or microplates, or any other  
15 surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex to the solid surface which is then washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes or overnight if  
20 more convenient) and under suitable conditions (e.g. from room temperature to about 37°C) to allow binding of any subunit present in the antibody. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710. The second antibody is linked to a reporter  
25 molecule which is used to indicate the binding of the second antibody to AGT-701, AGT-702, AGT-704, AGT-705, AGT-706, AGT-707, AGT-708, AGT-709 and AGT-710.

An alternative method involves immobilizing the target molecules in the biological sample and then exposing the immobilized target to specific antibody which may or may not be  
30 labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the

- 59 -

antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.

- 5 By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules.

10

- In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, 15  $\beta$ -galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted 20 above. In all cases, the enzyme-labelled antibody is added to the first antibody hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, 25 to give an indication of the amount of hapten which was present in the sample. A "reporter molecule" also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.

- Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be 30 chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody

- 60 -

absorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. As in the EIA, the fluorescent-labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining tertiary complex is  
5 then exposed to the light of the appropriate wavelength. The fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.

10

The present invention also contemplates genetic assays such as involving, for example, PCR analysis to detect *AGT-701*, *AGT-702*, *AGT-704*, *AGT-705*, *AGT-706*, *AGT-707*, *AGT-708*, *AGT-709* and *AGT-710* or their derivatives.

15 Real-time PCR is also particularly useful for assaying for particular genetic molecules.

The present invention is further described by the following non-limiting Examples.

- 61 -

### EXAMPLE 1

#### *Psammomys obesus*

In the following examples, *Psammomys obesus* rats were used for differential expression studies under different conditions. The rats are divided into three groups, based on metabolic phenotype, as follows:-

Group A animals : lean  
Group B animals : obese, non-diabetic  
10 Group C animals : obese, diabetic.

### EXAMPLE 2

#### *Sequence of Psammomys obesus AGT-701*

15 AGT-701 was identified using microarray analysis of red gastrocnemius muscle in exercise trained and control *P. obesus*.

The nucleotide sequence is as follows:-

20 GGACATCTTTTCAGCCATGAGGAGCTTTCTGGAAACTCGGAGTTGATACAG  
AAATATAGGAATATAATCACGCAGGCTCCTAACCTGGAGAACATTGAGCTG  
TACTGGAACAGCTACAACAACCGCCGAGACCTGAACTTCGAGCGAGGTGGT  
GAGATGACCCCTCAAGTGCCCTGTGATGCTGGTGGTAGGAGACCAAGCGCCT  
CATGAGGATGCCGTGGTGGAGTGTAACCTCAAACTGGACCCACACAGACC  
25 TCGTTCCTCAAGATGGCTGATTCCTGGAGGTCAGCCACAGCTGACCCAGCCA  
GGCAAGCTGACTGAGGCTTTCAAGTACTTNCTGCAAGGCATGGGCTACATG  
GCCTCCTCCTGCATGACTCGCCTATCGAGGTCTCGCACGGCATCTTTGACC  
AGCGCAGCATCCATTGAT [SEQ ID NO:1]

30

### EXAMPLE 3

#### *AGT-701 sequence homology*

N-myc downstream-regulated gene 2 (NDRG2)

35

- 62 -

#### EXAMPLE 4

##### *AGT-701 gene expression*

NDRG2 is a cytosolic protein of 371 amino acids with a molecular mass of 40.7 kDa  
5 (Zhou *et al.*, *Genomics* 73(1): 86-97, 2001) and is encoded by a 2.4 kb mRNA. By  
radiation hybrid analysis, Kalaydjieva *et al.* (*Am. J. Hum. Genet.* 67(1): 47-58, 2000)  
mapped the NDRG2 gene to chromosome 14q11.2. No information currently exists on the  
function of NDRG2. The human and mouse NDRG2 proteins are 92% identical (Zhou *et al.*, 2001). Rat NDRG2 was recently identified and has approximately 90% homology to  
10 the mouse and human protein (Boulkroun *et al.*, *J. Biol. Chem.* 277(35): 31506-31515,  
2002).

NDRG2 is part of the NDRG family, which includes NDRG1, NDRG3 and NDRG4. At  
the amino acid level, the four members share 53-65% identity (Kalaydjieva *et al.*, 2000;  
15 Zhou *et al.*, 2001). NDRG1 and NDRG3 belong to one subfamily and NDRG2 and  
NDRG4 to another. The N- and C-terminal regions are the most divergent regions between  
the four NDRG proteins, however the C-terminal five aa residues, Met-Glu-Val-Ser-Cys-  
COOH [SEQ ID NO:12] are conserved in all human and mouse proteins. There are three  
tandem repeats of GTRSRSHSTSE [SEQ ID NO:13] in the C-terminal region of NDRG1  
20 which are not present in NDRG2, NDRG3 and NDRG4.

All members of the NDRG family are cytosolic proteins (Qu *et al.*, *Mol. Cell. Biochem.*  
229(1-2): 35-44, 2002). Each of the four proteins contains an  $\alpha/\beta$  hydrolase fold which is  
common to a number of hydrolytic enzymes, suggesting that NDRG2 may have an  
25 enzymatic function (Boulkroun *et al.*, 2002). Hydrolases are enzymes that catalyze the  
hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc.  
Hydrolysis is the rupture of one or more chemical bonds by reaction with, and involving  
the addition of, the elements of water.

30 NDRG1 was the first of the family identified and has been shown to be involved in stress  
responses, hormone responses, cell growth, and differentiation (Zhou *et al.*, 2001 and

- 63 -

references therein). NDRG1 gene expression is up-regulated by many agents, such as reducing agents, tunicamycin, lysophosphatidylcholine, okadaic acid, calcium ionophore, DNA damaging agents, nickel compounds, forskolin, and androgens. The gene is also up-regulated during cell differentiation, in response to hypoxia, and at certain stages of the cell cycle in a p53-dependent manner. Over-expression of NDRG1 in tumor cells decreases the proliferation rate, enhances differentiation, and suppresses the metastatic potency of the cancer cells. In contrast, NDRG1 is repressed by N-myc and c-myc and in many tumor cells. A nonsense mutation in the NDRG1 gene is causative for hereditary motor and sensory neuropathy-Lom (HMSNL), a severe peripheral neuropathy characterized by Schwann cell dysfunction and progressive axonal loss in the peripheral nervous system. This suggests that NDRG1 functions in the peripheral nervous system necessary for axonal survival.

After the identification of NDRG1 in human and mouse, two other members of the family were then identified in mouse, Ndr2 and Ndr3 (Okuda and Kondoh, *Biochem. Biophys. Res. Commun.* 266(1): 208-215, 1999). In contrast to NDRG1, Ndr2 and Ndr3 were not under negative regulation by N-myc. Their expression during mouse development indicates that the three members of the family are under distinct spatio-temporal regulations, implying that genes of the NDRG family probably have tissue-dependent allotments of the possibly related functions (Okuda and Kondoh, 1999). Using the novel mouse sequences of Ndr2 and Ndr3 to search the human genome databases, Kalaydjieva *et al.*, 2000 identified the homologous human genes, which they referred as NDRG2 and NDRG3. Zhou *et al.*, 2001 cloned NDRG3 and NDRG4, studied the human NDRG gene family and further characterized NDRG4.

25

NDRG1, NDRG2 and NDRG3 are all expressed in a wide variety of tissues. NDRG2 is most highly expressed in adult skeletal muscle, brain and heart (Zhou *et al.*, 2001; Qu *et al.*, 2002), and NDRG3 is most highly expressed in brain and testis (Zhou *et al.*, 2001; Qu *et al.*, 2002). NDRG4 is specifically expressed in brain and heart (Zhou *et al.*, 2001; Qu *et al.*, 2002).

30

- 64 -

Zhou *et al.*, 2001 identified two forms of NDRG2, with and without a 14 amino acid insertion in the N-terminal region, located after amino acid number 25. This insertion was also present in mouse Ndr2. They designated the form with the insertion NDRG2 and the form without the insertion NDRG2<sup>var</sup>. Rat NDRG2 has four isoforms (Boulkroun *et al.*,  
5 2002). They differ in their 5'UTR sequence, which are either 87 or 50 nucleotides in length, and the presence or absence of the 42 base pairs (14 amino acids) insertion in the coding sequence at the same site as in human and mouse. The proteins are 357 or 371 amino acids in length. The insertion corresponds to the inclusion of exon 3 of the human DRG2 gene, suggesting an alternative splicing event. Sequences highly homologous to the  
10 2 rat NDRG2 5'UTR were found on different exons on the human NDRG2 gene, indicating that they might correspond to alternative 5' untranslated exons (Boulkroun *et al.*, 2002). This genomic organization strongly suggests the presence of alternative promoters which could direct expression of NDRG2 in a tissue specific and developmentally regulated manner.

15

NDRG2 has 34% identity to *Drosophila* MESK2, a component of the Ras pathway (Boulkroun *et al.*, 2002). Ras is an upstream regulator of phosphatidylinositol 3 kinase, and it may be hypothesized that NDRG2 may affect skeletal muscle insulin signalling through that pathway.

20

A Glucocorticoid Responsive Element (GRE) half-site (TGTTCT) is present in the human NDRG2 promoter (Boulkroun *et al.*, 2002). However, the glucocorticoid dexamethasone did not alter NDRG2 expression in RCCD2 cells, a rat kidney cortical collecting duct cell line, while the glucocorticoid-regulated gene *sgk* was induced.

25

In conclusion, NDRG2 belongs to a family of genes putatively involved in growth arrest and induction of cell differentiation, the Ras pathway, and the peripheral nervous system. Although it has strong homology to NDRG1, it is not under negative regulation by N-myc. NDRG2 is a cytosolic protein, probably with an enzymatic function.

30

#### EXAMPLE 5

***Red Gastrocnemius muscle: exercise training***

AGT-701 gene expression in skeletal muscle of *P. obesus* increased with exercise training, and was negatively correlated with blood glucose and the change in blood glucose after training. AGT-701 expression also correlated positively with energy expenditure (Figures 1 to 4).

**EXAMPLE 6*****Red Gastrocnemius muscle: fasting (24 h)***

10

AGT-701 expression was significantly lower in C fed *P. obesus*, compared to A fed animals and significantly higher in B fasted *P. obesus* compared to A fasted and C fasted animals. AGT-701 expression negatively correlated with body fat, body weight and blood glucose in the fed *P. obesus* (Figures 5 to 9).

15

**EXAMPLE 7*****Sequence of *Psammomys obesus* AGT-702***

AGT-702 was identified using microarray analysis of red gastrocnemius muscle in exercise trained and control *P. obesus*.

20

The nucleotide sequence is as follows:-

25

30

35

GCTGGTACCGGTCCGGAATTCCCGGGATATCGTCGACCCACGCGTCCGGTG  
GTGGAGAAGATCGCTCCTGCCGTGGTTTACATTGAACTGTATCGCAAACCTT  
CCTTTCTCGAAGAGGGAGGTGCCAGTGGCGAGTGGGTCCGGATTTATCGTG  
TCTGAGGATGGACTGATTGTGACCAATGCTCACGTGGTGACCAACAAAAAC  
AGGGTCAAGGTTGAGCTGAAGAATGGAGCAACCTATGAAGCTAAAATCAAG  
GATGTGGATGAAAAGGCAGACATCGCACTTATCAAAATTGACCACCAGGGA  
AAGCTGCCAGTCTTGCTGCTGGGCCGCTCCTCAGAGCTTCGACCAGGAGAG  
TTTGTGGTCGCCATCGGAAGCCCCTTTTCCCTTCAAAACACAGTCACCACT  
GGGATCGTCAGTACCACCCAGCGAGGCGGCAAAGAGCTGGGGC [SEQ ID  
NO : 2]

- 66 -

### EXAMPLE 8

#### *AGT-702 sequence homology*

Protease, serine 11 (PRSS11).

5

### EXAMPLE 9

#### *Gene expression as measured by SYBR green real time PCR:*

#### *Red Gastrocnemius muscle; Exercise Training*

10 AGT-702 gene expression in skeletal muscle of *P. obesus* increased after exercise training and was negatively correlated with body weight in exercise trained *P. obesus*. AGT-702 expression was positively correlated with energy expenditure, and negatively correlated with blood glucose and the training induced change in blood glucose in all *P. obesus* (Figures 10-14).

15

### EXAMPLE 10

#### *Sequence of AGT-704 Psammomys obesus*

AGT-704 was identified using microarray analysis of red gastrocnemius muscle in exercise  
20 trained and control *P. obesus*.

The nucleotide sequence is as follows:-

25 TGACATTTTCTTTCCACCTCTTATGATAGCTGATATATACTAAATCTTTAT  
ACAGAAATGTCAGTACTTGAACAAATTCAAAACACATTGGTTTATTAACCTT  
TTGGCTCATGCATGGTTTATTAGGTTCAAATTATACCTGATTCATCTATAT  
TTACTTTTAAAATGTGTGGTTTCCTCATTTTAAAAGTAAACTAAACAGTG  
CTTTTGGAAATTTCTAAGCTACTAATTGTTGATAGATACAGCCTGTGTCTAG  
TAAAATAGTTTGTGGGTGTGGGTCTATCTTTCCATGAAAAAGTGGGAGG  
30 TGTAAGTTAGTTTGGTTAGTGCCTAATAGTTAAATTTATATAAAATAAGAA  
TGAGCATTGGTATCTGTATGAAAGGGCCCTAAATCAAATGATTATCCAT  
AATCAATCTTTATTCTTGTTTTATAAAAACCAAAGGGCACTCATTGGTTAA  
GTGTGCTGAGATAGAAAAG [SEQ ID NO:3]

35

### EXAMPLE 11

- 67 -

### *AGT-704 sequence homology*

Mus musculus RIKEN cDNA 1200009K13 gene (1200009K13Rik), mRNA. There are no human matches with the *P. obesus* sequence. However when BLASTing the mouse  
5 sequence NM\_025814 against the NR database, it matches strongly to Homo sapiens CGI-55 protein mRNA and Homo sapiens PAI-1 mRNA-binding protein (PAI-RBP1). These are the same gene with the LocusLink and Unigene cluster calling it PAI-RBP1.

### **EXAMPLE 12**

10

### *AGT-704 gene expression*

PAI-RBP1 is a 387 amino acid protein (with additional six and/or 15 amino acids insert in some variants) that plays a role in regulation of mRNA stability. Regulation of mRNA stability is an important component of the regulation of gene expression and is known to  
15 have a significant role in normal physiology and development.

The PAI-RBP1 protein binds to an A-rich region in the 3' 134 nucleotides of the PAI-1 mRNA. This 134 nucleotides region is able to confer cyclic nucleotide regulation of mRNA stability and is, therefore, called the CRS (cyclic nucleotide-responsive sequence).  
20 The PAI-1 CRS includes a 75 nucleotide U-rich region at its 5' end and a 24 nucleotides A-rich region at its 3' end. Mutation of the A-rich portion reduces binding by PAI-RBP1 and eliminates cyclic nucleotide regulation of mRNA decay.

The amino acid sequence of PAI-RBP1 includes an RGG box at amino acid 343-359, as  
25 well as an Arg-rich (amino acid 126-137) and an RG-rich (amino acid 163-184) motif, which places it in the general category with RNA-binding proteins, even though it does not have other RNA binding motifs such as an RNA recognition motif (RRM) or K-homology (KH) domain. The potential protein kinase A phosphorylation site (RKES) at serine 74 is also important given that this protein could be regulated by cyclic nucleotides.

30

- 68 -

PAI-RBP1 includes blocks of sequence that are highly conserved in a number of metazoans including mammals, birds, *Drosophila* and *Arabidopsis*. Thus, PAI-RBP1 identifies a family of proteins with a previously unidentified domain that may define a new RNA-binding motif.

5

PAI-RBP1 has four splice variants, from two alternative splice sites, in both human and rat. An insertion of six amino acids after position 202 is found in some transcripts, and an insertion of 15 amino acids after amino acid 226 is found in some, both with or without the six amino acid insert.

10

PAI-RBP1 mRNA is expressed in a wide variety of tissues suggesting that it has a more general biological role involving regulation of mRNA stability or processes requiring interaction with RNA.

15 Plasmin is a broad spectrum protease. It is the major fibrinolytic enzyme in blood and also participates in a number of physiological and pathological processes involving localized proteolysis. Plasminogen is converted to plasmin by plasminogen activators (PAs), which are serine proteases and hydrolyze one peptide bond of plasminogen. Plasminogen activator activity is regulated by plasminogen activator inhibitor 1 (PAI-1). It is the mRNA  
20 of PAI-1 that PAI-1-RBP1 binds to. PAI-1 expression is also regulated by growth factors, cytokines and hormones including agents that regulate cAMP levels.

PAI-1 is consistently elevated in obesity and type 2 diabetes (Mertens and Van Gaal, *Obes. Rev.* 3(2): 85-101, 2002). There is a strong positive correlation between this elevated PAI-  
25 1 and the degree of hyperinsulinemia. Both modest and substantial weight loss have been found to significantly reduce PAI-1 levels. Recently it has been demonstrated that the adipocyte itself is able to produce PAI-1. Only the abdominal fat, not femoral subcutaneous fat, PAI-1 gene expression contributes to increases in plasma PAI-1 in obesity (Mavri *et al.*, *Diabetologia* 44(11): 2025-2031, 2001). Adipose tissue also  
30 produces several effector molecules that can up regulate PAI-1. These molecules include transforming growth factor  $\beta$ , TNF  $\alpha$ , angiotensin II and interleukin 6. Insulin stimulates

- 69 -

PAI-1 gene expression but glucose transport and PAI-1 gene expression are mediated by different insulin signaling pathways (Samad *et al.*, *Mol. Med.* 6(8): 680-692, 2000). The disturbances in the haemostatic and fibrinolytic systems in part explains why obese and type 2 diabetic patients are at risk for the development of cardiovascular diseases.

5 Increased PAI-1 levels in the blood vessel wall decreases local fibrinolysis which may elevate thrombus formation and the evolution of atherosclerotic plaques (Pandolfi *et al.*, *Arterioscler Thomb. Vasc. Biol.* 21(8): 1378-1382, 2001). Chronic inflammation has emerged as a new risk factor for the development of type 2 diabetes. Elevated levels of acute-phase proteins and PAI-1 predict type 2 diabetes independent of insulin resistance

10 and other known risk factors for diabetes (Festa *et al.*, 51(4): 1131-1137, 2002).

A 4G/5G polymorphism in the PAI-1 promoter is strongly linked to obesity, and a markedly increased risk for obesity is associated with the 4G allele in its homozygous form (Hoffstedt *et al.*, *Diabetologia* 45(4): 584-587, 2002). Regular exercise has been shown to

15 be effective for controlling elevated PAI-1 levels in subjects homozygous for the 4G allele (Vaisanen *et al.*, *Thomb. Haemost.* 82(3): 1117-1120, 1999).

### EXAMPLE 13

*Gene expression as measured by SYBR green real time PCR:*

20 *Red Gastrocnemius muscle; Exercise Training*

AGT-704 gene expression in skeletal muscle of *P. obesus* increased with exercise training. AGT-704 gene expression negatively correlated with blood glucose and positively correlated with energy expenditure in *P. obesus* (Figures 15 to 17).

25

### EXAMPLE 14

*Red Gastrocnemius muscle; Fasting (24 hr)*

There were no differences in AGT-704 gene expression between the fed or the fasted

30 groups of *P. obesus*, although there was a trend towards decreased expression in C fed *P.*

- 70 -

*obesus* compared to A fed ( $p=0.08$ ). However, AGT-704 gene expression showed a significant negative correlation with blood glucose in fed *P. obesus* (Figures 18 and 19).

### EXAMPLE 15

#### 5                                      *Sequence of AGT-705 Psammomys obesus*

AGT-705 was identified using microarray analysis of red gastrocnemius muscle in exercise trained and control *P. obesus*.

10    The nucleotide sequence is as follows:-

```
CGCAGATACTGCAGAGCTGACGCATTCTTTGCCTGGCATCTCAGCTTGCTA
GGTGTCTCATCTTCGCTCTGCGCTCGTGGCCTCCTCCAAGGCCTCCAGTCT
CCTTTAAGAAAACCTCAAGACCTGGGAAGCTACGATGCGAGCTTGATGCCGC
15 TACCCCTAGCAGGCTATGGACTTCCTGAGGGTCCCTCGGACTGTTGACACCCA
TTCCGATCCGCATCCTTCCAAGCTGATAAGCCCGGGACCCTAGGGCGGGGT
GCCCAGACTCATGTGTGACGCCCTTGCAAGTAAAACCCATTCCAGTGTGGT
TGCTTCTTTGCTGGGCTTTGGCCCATTTGATACACGAAGGATGACGATGC
TAGTTATGCAGCAGCCAACACACCTCCCCCAACTCTCCGCTGTCACTGGT
20 GGGCCCCACTGTCCAGGAAGCAGGTGTCCGGAAGTGCATCTTGGAGCAGA
GGGGCCATGAGAGGTGTGTGTATCCTGCCAGAAAGCAGCTGGACCACGACG
CTCCAAGATGAACCCACTGTATACAGAGGCATCATGGGAGTTGTTATGTC
AGGAGCATTCTAGACCCACGTGTACTTGAGCGTGGAAAGACAGAAGANANG
CGCAGAGACTGGGGCACTTGATCTGCTCACCATGATCGCCTGCACGGGTCT
25 CATCCAGTTCTTGCCTTAGGCTACAGTGGCGGTGTCCACGGGCTTGCCATT
CAACGTGCTCTCAGACCCAGATCGGGCTCACCCTGAGGAGAACCTTTTCA
CTTTGGTGGGTATGCAGAGGGAAGGGTCTCGACTCCAGAGACCTGGAGTCC
AAAGTTTGTTTTTTTTTTTATTTACCAGTAATTTATTTATTTTTTTTATTATT
AGTTATGAGTCCAAAGTTTAATACCATTCAGCTACTGCTGTCTGTCTGCT
30 TAGAGCCACAGCATGCAATGTGGCACCAAGGCATCCTTGCTCCTCACAGTTT
CACACTGTGGGAACAGGCATCCTTGTTCTTACAGATTAGCGCGAGGGAAAC
CAGAAATATTAAACACGCAGGGTTGTCTCTCAAAGGGAGAGGCACATACC
CTGTTTTCTCCTCCCGAAGGCTGGGAGCGGAGGTGTTTGATATCCTGGCTACC
TCTGTGCAATCTGTAGGCCATGTCTTAAGATGTAGCTGTGAGTCGGTAGT
35 GGAGCCGGAGCCGTGAGTCAAGTAGATTGGGGTTGTGGCATGCGCCTTTAAC
TCCATTTAATTCCAGCACTCTAGTGGTTTGGTACAGCAGCAGCAGCAGCGG
TTGCAGTGGCCCGGGGAAGTCTGAAGACCAGCTTTCATCCAGCACTCAG
GCAGCAAAGGCGGGTGGATTCTCTGAGTTCGAGGCCGGCCTGGTCTACAGA
GTGAGTCCAGNCNAGCCAGGGCTACAACAGAGAAANCCTCTCTATTGAAAA
40 ATAAATAAATTATAAAAAAAAAAAGGTGTCATGTGTCCTGTGTACTTTACA
AAGAATGTTGATGCTTAAGCTTTTTTGTGCACNCAAGAAAATTGTTTAACT
```

- 71 -

5 GGTGTCAGACTCCTGAAGTTTGAACCAGCACTTAGCCNGGCGTGGTGGCGC  
ACGCCTGTAATCCCAGCCCTCGGGAGGCAGAGGCAGGTGGATCTCTGAGTT  
AGAGGCCAGCCTGGTCTACAGAGTGAGTCCAGGACAGCCAGGATTACACAG  
AGAAACCCCGTCTCAAAAATGTAAAATAAATTAAAATAAAGTTTGAACCAA  
CAGTGTTTACTGAGTCGTGTTGAAACAGATTACCTTTTGGCTTCTCTTTGA  
TCATTATTCTACTGTGGTGTGAGCAGAGACCCCTCCAGCAGGTGGCCAACG  
TGAGAGTCTCAAGCCCGAGAAGGTAAGAATTTAAAAAAAAAAAAAAAAAA  
[SEQ ID NO:4]

10

#### EXAMPLE 16

##### *AGT-705 sequence homology*

The full clone sequence of AGT-705 matches a mouse mRNA clone BC030414 (not full length mRNA) but no human sequences on the GenBank database.

15

#### EXAMPLE 17

##### *Gene expression as measured by SYBR green real time PCR:*

##### *Red Gastrocnemius muscle; Exercise Training*

- 20 AGT-705 expression was not different between the exercise trained and the control *P. obesus*, although there was a tendency for expression to increase with exercise training (Figure 20).

**EXAMPLE 18*****Red Gastrocnemius muscle; Fasting (24 hr)***

In this study, there was no difference in AGT-705 expression between the fed *P. obesus*,  
5 however, there was a trend towards increased expression in the C fed *P. obesus*. AGT-705  
expression was significantly higher in the B fasted group when compared with the A fasted  
group and the C fasted group and gene expression was negatively correlated with blood  
glucose in the fasted *P. obesus* (Figures 21 to 23).

**EXAMPLE 19*****Sequence of AGT-706 Psammomys obesus***

AGT-706 was identified using microarray analysis of red gastrocnemius muscle in exercise  
trained and control *P. obesus*.

The nucleotide sequence is as follows:-

20 GTTGGGAAAGAATGAAGAAACAACCCGATGAATAGAAATGAAAAGCCTAA  
GCCAAATGGATTTCTGTTGAGATGTTGGATGAAAACAAGTATCCACTGTT  
TACCAACTTGACGAAAAATCTCAACTGAGGTTTGGCTGTTAAAAA  
ATTCACTGTGGCCTCTGTGCTTAATTGTCGTAAACCATTGTGACTGTTAC  
TGCTCAAAGTATCGTACTGTTCAATTAGTAACTACATCAGAATTGCACCGC  
TGCTGTTGGAAAAGCCAATAAAGAAACCCCCAGACTGCTGCTCAGCAAAT  
GTTAATAAAGTGTGCGCACCGTAGGCCTGTCCACCCAGTCACCAAGCAGC  
25 GTCCCTTTGTCTGCGAGTGGCTGTGGGTGTGATTNACCACCTCAGAGGTG  
CACAGCACCTGCTTGNGCCCTTAAGTGTGNGTCAGAAGACAAGCAGCTTC  
TCGGTAACCAACAACCTGCTTTTCGGAGCTCAGTGTTTAGGCTGTTTACT  
GAATCANATATGTAACCTCAGCACACATAAGCGAAGAGAGATTTTGGCTGC  
ACTGGCAAGAGTGAACCAAATTTACTTCTATTTTAAAGGCAGATCATA  
30 TTTAAGCATATAAGTAATTTATGGATATAAATTGTTGGATATTTATTTTA  
GTCTGAATATTTGTTTTTAAATTATTACATGTGTTCTCTATGTCTTTATC  
TCTGGAATAACGATGCCATTAACCACATGGCCATATGTTTTGAAAGTTGG  
GTGNAACAGAGGAAAAGTCATCCTTCTTGTTCTTGACTCCCTTTCTCTCA  
ACTACATGATAAGTCTATCAATAAAGCATTGACCTCAGCAGGGGCAGAA  
35 GCCTGNAAAGTTAGAAAACCTATTGACCACAGTAGACAATTGATTTCTTA  
GAAATAAGAAGTGAGAAGCAGCTGCTGNGCTGAGCAGGGGATGTAAACCA  
AGTCCAGATGCACCAACGTGAAGAGGCTTNTAGCAAAAATATGTTTGCCT  
CTCACCCCTGCACATGTTCTAGATGCTTAAAACAGCCACATGGCCCCGC

- 73 -

5 TGCGAGGACCTCGTAATGTTGTTGTTGTTGTTGTTGTTGTTAAAGGAGTT  
CTCACAAGCGTACAAGTGCAGCACTGAAAGTGGCTGAGGCCACAGTCCT  
CAGCACCCAAGTCTNTTCCGCAGCACGCCAAGCTGGTGTGTCCGGGTGN  
GTATGTCTGTGCTCAGTGCCAAGCTGGTGTGTTGGTCCCGTTGTATATTAT  
GTGCCCCAAGTGTTTTGGGGCANAGCTGACCCANGCTGGACACACTTCTT  
TTNGNCTTCGAGTTTACTGGTTGATNCAGNTAAAAATAAATTAATTAATT  
AAAGACTT [SEQ ID NO:5]

#### EXAMPLE 20

10 *AGT-706 sequence homology*

Human hypothetical protein FLJ20069 and mouse Ahi-1 (also called mouse 1700015F03).

#### EXAMPLE 21

15 *AGT-706 gene expression*

The Ahi-1 locus was initially identified as a common helper provirus integration site in Abelson pre-B-cell lymphomas and shown to be closely linked to the c-myb proto-oncogene. Proviral integration within the Ahi-1 region has also been shown in thymomas  
20 of T cell origin.

Jiang *et al.* (*J. Virol.* 76(18): 9046-9059, 2002) identified the murine gene (Ahi-1) targeted by these provirus insertional mutations. The Ahi-1 cDNA encodes a 1,047-amino-acid protein. The predicted Ahi-1 protein is a modular protein that exhibits several features of a  
25 signaling molecule. It contains one SH3 motif and seven WD40 repeats. The Ahi-1 gene is conserved in mammals and encodes two major RNA species of 5 and 4.2 kb and several other shorter splicing variants. The Ahi-1 gene is expressed in mouse embryos and in several organs of the mouse and rat, notably at high levels in the brain and testes.

30 The Ahi-1 proviral insertions were found at the 3' end of the gene, in an inverse transcriptional orientation, with most of them located around and downstream of the last exon, whereas another insertion was within intron 22. In addition, another previously identified provirus insertion site, Mis-2, was found to map within the 16th intron of the Ahi-1 gene. In tumor cells harboring insertional mutations in Ahi-1, truncated Ahi-1/viral

- 74 -

fused transcripts were identified, including some splicing variants with deletion of the SH3 domain.

In summary, Ahi-1 encodes a protein that exhibits several features of a signaling molecule  
5 and is targeted by provirus insertion. Ahi-1 may play an important role in signal transduction in normal cells and may be involved in tumor development, possibly in cooperation with other oncogenes (such as v-abl and c-myc) or with a tumor suppressor gene (Nf1).

10

#### EXAMPLE 22

*Gene expression as measured by SYBR green real time PCR:*

*Red Gastrocnemius muscle; Exercise Training*

AGT-706 gene expression increased in skeletal muscle of *P. obesus* after exercise training.  
15 In addition, AGT-706 gene expression was negatively correlated with blood glucose and positively correlated with insulin and energy expenditure in *P. obesus* (Figures 24 to 27).

#### EXAMPLE 23

*Red Gastrocnemius muscle; Fasting (24 hr)*

20

In this study, AGT-706 gene expression was significantly higher in the B fasted and C fasted groups, when compared to the A fasted group. AGT-706 gene expression was negatively correlated with blood glucose in fed *P. obesus*, and positively correlated with insulin in fasted *P. obesus* (Figures 28 to 30).

25

#### EXAMPLE 24

*Sequence of AGT-707 Psammomys obesus*

AGT-707 was identified using microarray analysis of red gastrocnemius muscle in exercise  
30 trained and control *P. obesus*.

- 75 -

The nucleotide sequence is as follows:-

```

5  GTNGAAGCNTAGGAGTTTCGAGGATGCGCCCGATGTCGAGCCGCTGGAACCC
   ACGCTTAGCAATATCATCGAGCAGCGCAGCCTTAAGTGGATCTTCGTCGGG
   GGCAAGGGTGGCGTTGGTAAGACCACCTGCAGCTGCAGCCTGGCGGTCCAG
   CTGTCTAAGGGACGTGAGAGTGTTCTAATCATTTCCACAGACCCAGCTCAC
   AACATCTCAGATGCATTTGACCAGAAGTTCTCCAAGGTGCCTACCAAGGTC
   AAAGGCTATGACAACCTCTTTGCTATGGAGATAGACCCGAGCCTGGGCGTG
10 GCAGAGCTCCCTGATGAAGTTCTTCGAGGAAGACAACATGCTGAGCATGGG
   CAAGAAGATGATGCAGGAGGCCATGAGCGCCTT [SEQ ID NO:6]
```

#### EXAMPLE 25

##### *AGT-707 sequence homology*

15 ASNA1: Human homolog of bacterial arsA arsenite transporter, ATP-binding.

#### EXAMPLE 26

##### *AGT-707 gene expression*

20 ASNA1 is the human homolog of the bacterial arsA gene. In *E. coli*, ArsA ATPase is the catalytic component of a multi-subunit oxyanion pump that is responsible for resistance to arsenicals and antimonials. The *E. coli* ars operon contains two regulatory (arsR and arsD) and three structural genes (arsA, B and C). The arsA gene codes for an oxyanion ATPase that associates with the protein encoded for by arsB, the channel-forming transmembrane  
25 protein. Together, the two proteins transport arsenite and antimonite out of the cells across the plasma membrane.

Human ASNA1 encodes a 332-amino acid polypeptide having an N-terminal ATP-binding cassette (ABC) domain and a C-terminal domain of unknown function (Kurdi-Haidar *et al.*, *Genomics* 36: 486-491, 1996). The protein sequence is highly homologous throughout  
30 both domains to hypothetical arsA proteins of *C. elegans* and yeast. Southern blot analysis indicated the existence of two closely related ARSA genes in the human genome. The existence of a second human ARSA protein was further supported by Western blot analysis, which demonstrated that anti-ARSA1 antibodies identify two proteins of 37 and

- 76 -

42 kD. Kurdi-Haider *et al.*, 1996 expressed ASNA1 and found that the resulting 37-kD protein had ATPase activity.

Northern blot analysis revealed that the ASNA1 gene is expressed in a variety of tissues, with highest expression in the cardiac and skeletal muscle (Kurdi-Haider *et al.*, 1996). Immunohistochemical analysis of normal human tissues detected ASNA1 only in the epithelial cells of the liver, kidney, and stomach wall, in the adrenal medulla, in the islet cells of the pancreas, in the red pulp of the spleen, and in cardiac and skeletal muscle (Kurdi-Haider *et al.*, *J. Histochem. Cytochem.* 46: 1243-1248, 1998d). In skeletal muscle the fibers were strongly positive. Interestingly, ASNA1 levels were markedly increased in breast fibroadenomas and carcinomas.

ASNA1 shows a cytoplasmic, perinuclear, and nucleolar distribution (Kurdi-Haider *et al.*, *J. Biol. Chem.* 273: 22173-22176, 1998a; Kurdi-Haider *et al.*, *J. Cell. Biochem.* 71: 1-10, 1998b). Since the nuclear membrane and the nucleolus were enriched for ASNA1, with no detectable protein in the nucleoplasm, suggests that the nuclear ASNA1 is bound and does not diffuse freely. The cytoplasmic ASNA1 is soluble. The ASNA1 at the nuclear membrane was associated with invaginations into the nucleus in interphase cells. These results and the fact that it is not found in the plasma membrane suggest that ASNA1 is a paralog rather than an ortholog of ArsA and that it probably plays a different role in human cells than does the ArsA protein in bacteria. In human cells it appears to play a role in the nucleocytoplasmic transport of a nucleolar component.

Kurdi-Haider *et al.*, 1998a characterized purified recombinant ASNA1. They determined that the ATPase activity increases in the presence of sodium arsenite (but not antimonite) and that Vmax rather than ATP affinity is enhanced. Human ASNA1 is an arsenite-stimulated rather than an arsenite-dependent ATPase, and has significant basal ATPase activity even in the absence of oxyanions. Kurdi-Haider *et al.*, 1998a found that the active species is likely a dimer or tetramer.

- 77 -

Kurdi-Haidar *et al.*, *Somat. Cell Molec. Genet.* 24: 307-311, 1998c mapped the ASNA1 gene to chromosome 19q13.3 and determined that it contains four exons and spans 6 kb.

#### EXAMPLE 27

5

##### *Mouse ASNA1 gene*

Mouse Asna1 encodes a 348-amino acid protein sharing 27% and 99% identity with the *E. coli* and human proteins, respectively (Bhattacharjee *et al.*, *Gene* 272: 291-299, 2001). Northern blot analysis detected a 1.3-kb transcript in mouse at highest levels in kidney and  
10 testis, moderate levels in brain, liver, lung, and skin, low levels in heart, small intestine, spleen, stomach, and thymus, and negligible levels in skeletal muscle. Bhattacharjee *et al.*, 2001 mapped the mouse Asna1 gene to the C3-D1 region of chromosome 8, and determined that it consists of seven exons spanning over 7 kb.

15

#### EXAMPLE 28

##### *Gene expression as measured by SYBR green real time PCR:*

##### *Red Gastrocnemius muscle; Exercise Training*

AGT-707 gene expression in skeletal muscle of *P. obesus* increased with exercise training.  
20 There were no correlations between gene expression and other phenotypic variables (Figure 31).

- 78 -

**EXAMPLE 29*****Red Gastrocnemius muscle; Fasting (24 hr)***

There were no differences in AGT-707 gene expression between the fed groups or the  
5 fasted groups, although there was a trend for increased expression in group A compared to  
group B and C *P. obesus* in the fed state ( $p=0.075$  and  $p=0.055$ , respectively). AGT-707  
gene expression was negatively correlated with body weight in the fed *P. obesus* (Figures  
32 and 33).

10

**EXAMPLE 30*****Sequence of AGT-708 Psammomys obesus***

AGT-708 was identified using microarray analysis of red gastrocnemius muscle in exercise  
15 trained and control *P. obesus*.

The nucleotide sequence is as follows:-

20

25

30

35

```
AAAATTTTACAAATGAGTGTGAATTGCATTCTGATATAATAATTATCACCC
CACCACACTTTTACTGACACTGTTGATGGCCTATGCTGTGTTTTACATCA
CAATTCTTGTATGGAAAAATTTCTGTGGCCTGTGTAACCCCTCTGGTCAGT
ATTATGAAACCACTATCTTTGGTGATAAATAAGGTTCCGGTAAGATGCC
AGGGTTCATGAGTATGGCACAATAACAGAGGACAGGAGGCCTTCACGACG
AAGGAGCCCGTAAGTGGCCTGGAGGGCAGATGCAGTTCCAGGTCAAGAA
AAGAGCAGCTTTTTCAACAGGCAGTCTGTGGGTATGATGGGAACCTCAGCCT
GTCTCTGTAGTTATGGACAGCGTGGCAGGTGACTGTGCCCACATCTTCCTA
TACAGTGCTTTTTTTTACTGACTGGAAGTACGTGAATCTCACTTAGTCCC
CAACTGGACGTTTTTCTGGAAAAACAAAGCAAATGTTAAAGTATGTCTTTCT
GGATATAGGCCAGNAGNAAATACATTAAGAATGAGAGGCCTTGCTTTGATC
30 TCAGCCATTGGAGGCTAGAAAAAATTGAAAGGAACCTTCCTGTTGATAGA
CTCAAAGCCGTGAACAGAAGCCTCTTGCCCTGTTTCAGACAATCTCTGGTA
ATCTACTGACAATATCCAACAGTTTCGATGTCTTGTTTAACTACCCTGGT
AGCTTTCTTGTGGATTTGAAGTTCATTTTTAAAGCTGTGGAATTTCAAAC
GAATTCACGTGCATTTTGTAAGTTTCAGAACCAAGTGCTGAGTCTGTGTGG
35 CAGGTTTTTTTACC CGGTGATATACTATTACAAATGCATGTGGTGCCATG
CTTGCTTCAAATATATAAGTAGTGCTAAATGGATAAGTCATATGGAGCTT
TTGATTTAG [SEQ ID NO:7]
```

- 79 -

### EXAMPLE 31

#### *AGT-708 sequence homology*

Protein kinase inhibitor  $\alpha$  (PKI $\alpha$ ).

5

### EXAMPLE 32

#### *AGT-708 gene expression*

10 cAMP-dependent protein kinases co-ordinate cellular responses to hormones and neurotransmitters by altering processes such as cell division, membrane permeability and transcription. Most of the effects of cAMP in the eukaryotic cell are mediated through the phosphorylation of target proteins on serine or threonine residues by the cAMP-dependent protein kinase (EC 2.7.1.37). The inactive cAMP-dependent protein kinase is a tetramer composed of two regulatory and two catalytic subunits. The cooperative binding of four  
15 molecules of cAMP dissociates the enzyme in a regulatory subunit dimer and two free active catalytic subunits. In the human, four different regulatory subunits (PRKAR1A, PRKAR1B, PRKAR2A, and PRKAR2B) and three catalytic subunits (PRKACA, PRKACB and PRKACG) have been identified.

20 Members of the cAMP-dependent protein kinase inhibitor family are specific and extremely potent competitive inhibitors of cAMP-dependent protein kinase activity. These proteins interact with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulatory chains. The inhibitory site contains regions very similar to the hinge regions (sites that directly interact with the enzyme active site) and "pseudosubstrate  
25 site" of the regulatory chains; but unlike these chains, PKI does not contain cAMP-binding sites. The arginine residues within the inhibitory site are essential for inhibition and recognition of the enzyme active site.

- 80 -

### EXAMPLE 33

#### *Cloning*

Using the mouse protein kinase inhibitor- $\alpha$  to screen a human neuroblastoma cell line  
5 cDNA library, Olsen and Uhler (*Molec. Endocr.* 5: 1246-1256, 1991) isolated clones  
encoding human PKIA. The deduced 75-amino acid PKIA protein shares 100% and 97%  
sequence identity with the rabbit and mouse homologs, respectively. Northern blot analysis  
detected major 4-kb and minor 2-kb PKIA transcripts in skeletal muscle. Using kinase  
assays with transfected COS cells, Olsen and Uhler, 1991 verified that the PKIA cDNA  
10 produces a heat-stable inhibitor of protein kinase. Protein extracts inhibited both the  $\alpha$   
(601639) and  $\beta$  (176892) isoforms of the protein kinase catalytic subunit with equal  
efficacy. Using a transcriptional activation system, Olsen and Uhler, 1991 demonstrated  
that elimination of a conserved alternative translation start site in PKI increased the  
inhibitory activity of the PKI expression vector.

15

### EXAMPLE 34

#### *Gene expression as measured by SYBR green real time PCR:*

#### *Red Gastrocnemius muscle; Exercise Training*

20 AGT-708 gene expression in skeletal muscle of *P. obesus* was negatively correlated with  
activity and the change in carbohydrate oxidation after exercise training, and was  
positively correlated with energy expenditure and the change in fat oxidation after exercise  
training when all animals were analyzed together. AGT-708 gene expression positively  
correlated with food intake and the change in fat oxidation and negatively correlated with  
25 the change in carbohydrate oxidation in the exercise trained *P. obesus* (Figures 34 to 40).

- 81 -

### EXAMPLE 35

#### *Red Gastrocnemius muscle; Fasting (24 hr)*

AGT-708 gene expression was significantly higher in the B fasted and C fasted groups  
5 when compared to the A fasted group. AGT-708 gene expression positively correlated with  
blood glucose in fasted *P. obesus* (Figures 41 and 42).

### EXAMPLE 36

#### *Sequence of AGT-709 Psammomys obesus*

10

AGT-709 was identified using microarray analysis of red gastrocnemius muscle in exercise  
trained and control *P. obesus*.

The nucleotide sequence is as follows:-

15

TGAGATAGCTACTCCATAAGCCTCTGAAGAGCAATAGCTAATTTATTATTA  
CTGTAATTNTTTTAAAGGCTTTAAAGTGCCTCGGGGGTTCCTTGAAACTAA  
TTTTCTACTTCTGGGATTCCCTGGATTCTTTATAAGAGATGGTGACATGAC  
TAGGGAAATTCTTTTTTTAGTATGAAAATTGTCCCTTCAATACTTTTCTCT  
20 TACTGGCATTGAATTATCACAGAGACAGAAAATTGGTAATTTTTTTAATTT  
CTAACTCTCCCAGAAAACCTCTTGCCTAGTATTTATTTGATGTGCTTTA  
ACCATGGGAGGAGGGGTGGGGGGGAACCTCATTCAAGCTGCCAGTATTTTG  
ATCTACAACCTGTAGCA [SEQ ID NO:8]

25

### EXAMPLE 37

#### *AGT-709 sequence homology*

Human KIAA0663

- 82 -

### EXAMPLE 38

***Gene expression as measured by SYBR green real time PCR:  
Red Gastrocnemius muscle; Exercise Training***

5 There was no difference in AGT-709 gene expression in exercise trained animals when compared to controls. A significant positive correlation between AGT-709 gene expression and body weight and energy expenditure was found when all animals were analyzed together. AGT-709 expression in exercise trained animals showed a positive association with body weight, and the change in glucose and in body weight after exercise training  
10 (Figures 43 to 47).

### EXAMPLE 39

***Red Gastrocnemius muscle; Fasting (24 hr)***

15 AGT-709 expression was significantly lower in the C fed *P. obesus* than the A fed *P. obesus*, although there were no differences in gene expression between the fasted groups. AGT-709 expression was negatively correlated with body weight and blood glucose in fed *P. obesus* (Figures 48 to 50).

### EXAMPLE 40

***Sequence of AGT-710 Psammomys obesus***

AGT-710 was identified using microarray analysis of red gastrocnemius muscle in exercise trained and control *P. obesus*.

25 The nucleotide sequence is as follows:-

30 CCCACGCAGTCCGGGTGGCTCTGCAGCACAAATTTAGGCCTTGGAGGAGCTG  
TGGTTGTCAACCCTCTACAANATGGGCTTCCCCGAAGCGGNCAGCTCCTTCA  
GAACACACCANATTTTCGGCTGCTCCACACAGCTCTGCAAGGGATGGATTCA  
AGGCCAATCTTGTCTTTAAGGAGATCGAGAAGAAGCTTGAAGAGGAAGGGG  
AACAGTTCGTGAAGAAGATCGGTGGGATTTTGCCTTCAAAGTGAAGGACG  
GCCCTGGAGGCAAAGAAGCCACCTGGGTGGTGGATGTGAAGAATGGCAAGG

- 83 -

GATCCGTGCTTCCCAACTCAGATAAGAAGGCTGACTGCACAATCACCATGG  
CCGACTCCGACTTGCTGGCTCTGATGACTGNCAAAATGAACCCTC [SEQ  
ID NO: 9]

5

#### EXAMPLE 41

##### *AGT-710 sequence homology*

Sterol carrier protein 2 (SCP2)

10

#### EXAMPLE 42

##### *AGT-710 gene expression*

Sterol carrier protein 2 (SCP-2, SCP2) is also known as Nonspecific lipid-transfer protein, mitochondrial precursor (NSL-TP) and Sterol carrier protein X (SCP-X, SCPX) (SCP2  
15 Genecard record, Genecards Website, Weizmann Institute of Science; Human SCP-2 (NLTP\_HUMAN) record from SWISS-PROT database, ExPasy Website). The SCP-2 gene is a fusion gene that has two initiation sites. The gene encodes two proteins: SCP-2 and SCP-X. Both proteins share the same C-terminal 13 kDa (123 aa) sequence. The SCP-2 transcript encodes a 15 kDa (143 amino acid) pro-SCP-2 protein which is post-  
20 translationally cleaved to form the mature 13 kDa SCP-2 protein. The longer isoform, SCP-X, is translated into a 58 kDa (547 amino acid) protein and is partially cleaved to form two proteins - the 13kDa SCP-2 and a 45 kDa (404 amino acid) protein (Gallegos *et al.*, *Prog. Lipid. Res.* 40(6): 498-563, 2001). The latter is a 3-ketoacyl-CoA-thiolase specific for branched chain acyl CoAs (Stolowich *et al.*, *Cell Mol. Life Sci.* 59(2): 193-212,  
25 2002). In most tissues however, the majority of the 58 kDa protein remains intact (Stolowich *et al.*, 2002).

The 13 kDa SCP-2 binds a number of different ligands such as fatty acids, fatty acyl CoAs, cholesterol and phospholipids. It is thought that the 13 kDa SCP-2 facilitates the  
30 intracellular transport of lipids such as cholesterol between membranes. SCP-2 has been shown to also interact with a number of other ligands, and other possible physiological functions are being examined (Gallegos *et al.*, 2001).

Related genes proteins that also contain the C-terminal SCP-2 domain are:  
DHB4 HUMAN: 17 $\beta$  -hydroxysteroid dehydrogenase IV (DBH4 record from Pfam  
database of protein families Website, Sanger Centre; Gallegos *et al.*, 2001) (the C-terminal  
5 SCP-2 domain is known to be required for peroxisomal import of this protein) and  
UNC-24 protein from *C. elegans* (this protein consists of an N-terminal SPFH (or band 7)  
domain and a SCP-2-like C-terminal domain. The human homologue of this protein is  
stomatin-like protein (hSLP). Its function is unknown (Gallegos *et al.*, 2001; Barnes *et al.*,  
*J. Neurochem.* 67(1): 46-57, 1996).

10

### EXAMPLE 43

#### *Chromosomal Location and Gene Structure*

The SCP-2 gene is located at chromosome 1p32 (Vesa *et al.*, *Hum. Molec. Genet.* 3: 341-  
15 346, 1994; SCP2 Genecard record, Genecards Website, Weizmann Institute of Science;  
Sterol Carrier Protein 2 record, OMIM Website). It consists of 16 exons and 15 introns in  
humans, mice, rats and chickens (Ohba *et al.*, *Genomics* 24: 370-274, 1994). The mouse  
homologue is found on chromosome 4 (Welch *et al.*, *Genome* 7: 624-625, 1996). There are  
2 promoter regions that initiate at least 4 mRNA species (Stolowich *et al.*, 2002). Two  
20 alternatively polyadenylated mRNA transcripts (mRNAs of 2.8kB and 2.2 kb) encode the  
58 kDa SCP-X protein, and two alternatively polyadenylated transcripts (mRNAs of 1.5 kb  
and 0.9 kb) encode the 15 kDa pro-SCP-2 protein (Stolowich *et al.*, 2002). Another study  
(Yamamoto *et al.*, *Proc. Natl. Acad. Sci. USA* 88(2): 463-467, 1991) identified a further  
two transcripts in the liver (1.8 kb and 3.2 kb species) where the 1.8kb isoform was most  
25 abundant. Little is known about the transcriptional regulation of the gene (Gallegos *et al.*,  
2001].

#### EXAMPLE 44

##### *Structural Features*

5 The secondary and tertiary structures for the 13 kDa molecule are available (Stolowich *et al.*, 2002; Szyperski *et al.*, *FEBS Lett.* 335(1): 18-26, 1993), however no structures are available for the 15 kDa, 45 kDa or 58 kDa molecules. At the protein sequence level the SCP-X protein consists of 3 domains (SCP-2 record from Pfam database of protein families Website, Sanger Center):

- 10
- Thiolase N-terminal domain (residues 11-240).
  - Thiolase C-terminal domain (residues 245-402).
  - SCP-2 at the C-terminal of the protein (residues 433-543).

15 The mature 13 kDa SCP-2 protein consists of only the SCP-2 domain. A tertiary structure is available for this molecule (Stolowich *et al.*, 2002). Functionally important structural elements that have been identified by elucidation of the structure are:-

- 20
- The N-terminal 32 residues form an amphipathic helix, one face of which is a membrane binding domain that binds to anionic phospholipids at membrane surfaces.
  - The hydrophobic faces of the N-terminal amphipathic helices plus  $\beta$ -strands 4,5 and  $\beta$ -helix D form a ligand-binding cavity able to accommodate multiple types of lipids (fatty acids, acyl coAs, cholesterol, phospholipids, isoprenoids).
  - 25 • The C-terminus is highly hydrophobic and it is thought to form a hydrophobic cap that closes around the ligand upon binding.

- 86 -

#### EXAMPLE 45

##### *Putative biochemical function*

Gallegos *et al.*, 2001 and Stolowich *et al.*, 2002 have reviewed the various functions of  
5 SCP-2. In summary:-

- SCP-2 is believed to affect cholesterol synthesis - overexpression in mice of the rat SCP-2 gene by adenoviral infection increased liver cholesterol levels by 70% and decreased liver cholesterol synthesis by 60% (Zanlungo *et al.*, *Gastroenterology*  
10 *119*(6): 1708-17-19, 2000).
- SCP-2 (Fuichs *et al.*, *Biochem. J.* 336(1): 33-37, 1998; Publielli *et al.*, *Biochem. J.* 317(3): 681-687, 1996; Kawata *et al.*, *Clin. Chim. Acta* 197(3): 201-208, 1991; Fuchs *et al.*, *J. Biol. Chem.* 276(51): 48058-48065, 2001) and SCP-X (Bun-ya *et al.*, *J.*  
15 *Biochem. (Tokyo)* 123(2): 347-352, 1998; Ferdinandusse *et al.*, *J. Lipid. Res.* 41(3): 336-342, 2000; Wanders *et al.*, *J. Inherit. Metab. Dis.* 21(3): 302-305, 1998) participate in different aspects of bile acid synthesis.
- SCP-2 is believed to be involved in transport of cholesterol from ER to bile (Ito *et al.*,  
20 *Gastroenterology* 110(5): 1619-1627, 1996).
- SCP-2 and possibly SCP-X and pro-SCP-2 are believed to be involved in triacylglyceride formation (Seedorf *et al.*, *Genes Dev.* 12(8): 1189-1201, 1998; Atshaves *et al.*, *J. Lipid Res.* 40(4): 610-622, 1999; Murphy and Schroeder, *Biochim.*  
25 *Biophys. Acta.* 1345(3): 283-292, 1997; Starodub *et al.*, *Am. J. Physiol. Cell Physiol.* 279(4): C1259-1269, 2000).
- SCP-2 and possible SCP-X and pro-SCP-2 are believed to participate in peroxisomal fatty acid oxidation (Seedorf *et al.*, 1998; Schroeder *et al.*, *Biochemistry* 34(37):  
30 11919-11927, 1995; Ossendorp *et al.*, *Arch. Biochem. Biophys.* 334(2): 251-260, 1996).

- SCP-2 is thought to facilitate cholesterol transport to mitochondria and be involved in regulating steroidogenesis (Yamamoto *et al.*, *Proc. Natl. Acad. Sci. USA* 88(2): 463-467, 1991; Yamamoto *Hokkaido Igaku Zasshi* 67: 839-848, 1992).
- 5
- The 58 kDa SCP-X is one of three 3-ketoacyl-CoA thiolases found in peroxisomes. SCP-X is believed to play an exclusive role in peroxisomal branched chain fatty acid oxidation (Antonenkova *et al.*, *J. Biol. Chem.* 272(41): 26023-26031, 1997; Antonenkova *et al.*, *Protein Expr. Purif.* 18(3): 249-256, 2000; Wanders *et al.*, *Biochem. Biophys. Res. Commun.* 236(3): 565-569, 1997) and in oxidation of the branched side chain of cholesterol to form bile acids (Fuchs *et al.*, 2001; Bun-ya *et al.*, 1998; Ferdinandusse *et al.*, 2000).
- 10

#### EXAMPLE 46

15

##### *Scp2 Knockout Mice*

*scp2* null mice show a severe block at the level of thiolytic cleavage in pristanic acid  $\beta$ -oxidation and lack normal peroxisomal degradation of the cholesterol side chain in bile acid synthesis. The knockout mice show spontaneous peroxisome proliferation and increased mRNA levels of genes regulated by PPAR $\alpha$ . The *scp2* null phenotype is similar to that seen in acyl-CoA oxidase (ACO) null mice (Kannenberg *et al.*, *J. Biol. Chem.* 274(50): 35455-35460, 1999). The *scp2* null mice also have affected peroxisomal  $\alpha$ -oxidation of phytanic acid (Atshaves *et al.*, 1999). Whether these phenotypes are secondary affects of the gene knockout has yet to be clarified (Seedorf *et al.*, *Biochim. Biophys. Acta.* 1486(1): 45-54, 2000).

- 20
- 25

#### EXAMPLE 47

##### *Tissue distribution*

The human SCP2 gene was cloned from the liver (Yamamoto *et al.*, 1991). The protein has been found most highly expressed in liver, intestine, adrenal and kidney (Baum *et al.*, *J.*

- 30

*Lipid. Res.* 34(5): 729-739, 1993). It is also expressed in lung, brain, testes, ovary and heart, fibroblasts, and placenta (Human SCP-2 (NLTP\_HUMAN) record from SWISS-PROT database, ExPasy Website). EST data from normal human tissues in Unigene indicate that the gene is expressed in bone marrow, brain, heart, skeletal muscle, liver, pancreas, prostate, kidney, and lung (SCP2 Genecard record, Genecards Website, Weizmann Institute of Science).

#### EXAMPLE 48

##### *Cellular Localization*

10

The identical C-termini of both SCP-2 and SCP-X contain an SKL peroxisomal targeting signal, however, as much as half of the total SCP-2 is located outside the peroxisome. The SCP-2 N-terminal presequence in the pro-SCP-2 protein strongly modulates intracellular targeting coded for by the C-terminal peroxisomal signal sequence (Gallegos *et al.*, 2001; 15 Stolowich *et al.*, 2002). Other studies indicate that mammalian SCP-2 is found in the cytoplasm or the mitochondria and that SCP-X is found in peroxisomes (Baker *et al.*, *DNA Cell Biol.* 10(9): 695-698, 1991; Interpro database of proteins [<http://www.ebi.ac.uk/interpro/Ientry?ac=IPR003033>]).

20

#### EXAMPLE 49

##### *Role in disease*

SCP-2 levels are altered in diseases where lipid metabolism is abnormal, such as diabetes, Zellweger, Niemann Pick C (NPC) and atherosclerosis (Stolowich *et al.*, 2002). SCP-2 is 25 present in low levels in Zellweger syndrome but is not causal of this syndrome in which the cells are deficient in peroxisomes (SCP2 Genecard record, Genecards Website, Weizmann Institute of Science). Zellweger patients have no detectable 15 kDa pro-SCP-2 protein or the mature 13 kDa SCP-2 and are deficient in very long chain fatty acid oxidation (Wirtz, *Biochem. J.* 324(2): 353-360, 1997; van Heusden *et al.*, *J. Biol. Chem.* 30 265(7): 4105-4110, 1990).

The SCP-X/SCP-2 gene was investigated as a candidate gene for infantile neuronal ceroid lipofuscinosis. However, despite the gene mapping to the same chromosomal location as markers for this disease, no association could be found between mutations in the SCP-2/SCP-X gene and the disease (Vesa *et al.*, 1994).

5

NPC1 disease is caused by a mutation in the NPC protein. In this disease cholesterol accumulates in liver lysosomes and the Golgi. This disease shows markedly reduced levels of hepatic 13 kDa SCP-2 as well as accumulation of lipids in lysosomes and Golgi (Roff *et al.*, *J. Biol. Chem.* 267(22): 15902-15908, 1992).

10

#### EXAMPLE 50

##### *Relationship to obesity or diabetes*

Streptozotocin-induced diabetes in rats decreased liver levels of SCP-2 by 60-90% and ovarian levels by 60% (McLean *et al.*, *Biol. Reprod.* 55(1): 38-46, 1996). Reduced 13 kDa SCP-2 expression in pregnant diabetic mice was associated with pregnancy loss (McLean *et al.*, 1996).

15

#### EXAMPLE 51

##### *Gene expression as measured by SYBR green real time PCR:*

##### *Red Gastrocnemius muscle; Exercise Training*

20

AGT-710 gene expression in skeletal muscle of *P. obesus* increased with exercise training. Gene expression was positively correlated with energy expenditure when all *P. obesus* were analysed together. Gene expression was negatively correlated with blood glucose and activity when all *P. obesus* were analyzed together. Gene expression was positively correlated with fat oxidation and the change in fat oxidation in exercise trained *P. obesus* (Figures 48 to 53).

25

- 90 -

## EXAMPLE 52

### *Red Gastrocnemius muscle; Fasting (24 hr)*

AGT-710 gene expression was significantly lower in C fed *P. obesus* when compared to A  
5 fed *P. obesus*. AGT-710 gene expression was negatively correlated with body weight and  
blood glucose in fed *P. obesus*. There were no differences in gene expression between the  
fasted groups, and no correlations with phenotypic variables (Figures 54 to 59).

## EXAMPLE 53

### 10 *cDNA microarray production*

RNA extracted from *P. obesus* was used to generate a cDNA library in the pCMV-SPORT  
6 Vector (Invitrogen Life Technologies). Individual cDNA clones were arrayed into 384  
well plates (The Australian Genome Research Facility, Queensland, Australia). The clones  
15 were then PCR amplified using vector complimentary primers (SP6 5'ATT TAG GTG  
ACA CTA TAG 3' [SEQ ID NO:10]; T7: 5'-TAATACGACT CACTATAGGG-3' [SEQ ID  
NO:11]). PCR amplification of each clone was performed in a GeneAmp PCR System  
9700 thermal cycler (PE Applied BioSystems, Sunnyvale, CA) for 35 cycles of  
denaturation at 95°C for 30 sec, annealing at 56°C for 30 sec and extension at 72°C for 120  
20 sec. A final extension step was performed at 72°C for 5 min. Products were visualized by  
TAE agarose gel (1.5% w/v) electrophoresis at 6V/cm for 90 min to ensure successful  
amplification had taken place.

PCR products were purified using the ArrayIt vacuum manifold system (TeleChem  
25 International, Sunnyvale, CA) and resuspended in 20 µL of 1X spotting solution  
(TeleChem) at a concentration of 0.5 mg/ml in 384 well plate format. 5 µL of the  
resuspended purified cDNA solution was transferred to 384 well uniplates (Whatman Inc,  
Clifton, USA). This cDNA was arrayed onto Super Amine Microarray Substrates  
(TeleChem) using a Chip Writer Pro robotic arrayer (Virtek, Toronto, Canada) fitted with  
30 16 Stealth SMP-03 quill tipped microarray pins (Telechem). The distance between adjacent  
cDNA spots was 200 µM. Each pin drew 0.25 µL of cDNA and deposited approximately

- 91 -

0.6 nL on each slide. Humidity was maintained between 55-65% during printing. Approximately 12,000 elements were printed per microarray. Spotted DNAs were allowed to dry overnight, after which the slides were washed and blocked as recommended by the manufacturer (TeleChem).

5

#### EXAMPLE 54

##### *RNA Extraction*

Total RNA was extracted from tissue in a two-step process utilising Trizol (Invitrogen Life Technologies, Carlsbad, USA) and RNeasy (Qiagen, Hilden, Germany) protocols. The tissue samples were lysed in 1.5 ml of Trizol (Invitrogen Life Technologies) and homogenised using a Ystral Homogeniser (model D-7801, Dottingen, Germany). 300 µL of chloroform was added to the homogenate, which was then mixed, transferred into a fresh 2 ml tube and incubated at room temperature for 3 min. The homogenates were then separated by centrifugation at 13 000xg for 15 min (4°C). Following centrifugation the aqueous supernatant was collected in 2 ml tubes and an equal volume of 70% v/v ethanol added, with the solution mixed by pipetting. 700 µL of the sample was then transferred *via* pipette into RNeasy kit mini spin columns (Qiagen) placed in 2 ml tubes (supplied) for purification. Initially the sample was centrifuged at 10 000xg for 20 sec. The flow-through was then poured back into the column and the centrifugation repeated. Further purification was performed according to manufacturer's instructions and the RNA was eluted using RNAase free water.

Following purification, total RNA integrity, quantity and concentration was assessed using the RNA 6000 Nano Assay (Agilent Technologies, Palo Alto, USA) with the Agilent 2100 Bioanalyser (Agilent Technologies) as per the manufacturer's instructions. This system utilises capillary electrophoresis to separate and detect nucleic acid fragments by size through the interconnected micro channels on a Nano chip (Agilent Technologies). Good quality RNA is signified by an electropherogram displaying a marker peak, and two ribosomal peaks of which the 18s band is at an approximate ratio of 1:2 to the 28s band.

**EXAMPLE 55*****Indirect labeling of cDNA***

Fluorescently labelled cDNA was prepared from 20 µg of total RNA using an indirect  
5 labelling method. cDNA synthesis was performed in a 30 µL reaction containing 5 µg  
oligo-dT primer, 400U SuperscriptII (Invitrogen), 1x first strand buffer, 0.01 M DTT, 0.5  
mM of each dATP, dCTP and dGTP, 0.150 mM dTTP (Amersham, Buckinghamshire,  
UK) and 0.2 mM aminoallyl-dUTP (Sigma, St. Louis, MO). Synthesis was conducted in a  
GeneAmp PCR System 9700 (PE Applied Systems) at 42°C for 2 hours. The reaction was  
10 stopped by addition of 5 µL of 0.5 M EDTA and RNA was hydrolyzed by addition of 20  
µl of 1 M NaOH at 70°C for 20 minutes. The reaction was neutralized with 25 µL of 1 M  
HEPES and the cDNA was purified using QIAGEN PCR purification kits according to  
manufacturer's instructions and eluted in nuclease-free water. The cDNA was concentrated  
using Microcon30 spin columns (Millipore, Bedford, MA) and the volume retrieved dried  
15 down under vacuum. The cDNA pellet was resuspended in 0.09 M sodium bicarbonate and  
coupled to Cy3 or Cy5 monofunctional NHS ester reactive dye (Amersham). The coupling  
reaction was conducted in the dark for 1 hour.

Dye-coupled cDNA was purified using Qiagen PCR purification columns, combined and  
20 added to 10 µg of Human Cot1 DNA (Invitrogen Life Technologies). The cDNAs were  
again concentrated with Microcon 30 spin columns (Millipore). The cDNA was hybridized  
in a 40 µL volume containing the labeled cDNA, 20X SSC, 8 µg PolydA, 2.5x Denhardt's  
solution, 4 µg yeast tRNA and 10% w/v SDS. The cDNA was then denatured at 98°C for 2  
min and maintained at 60°C until required. 38 µL of the hybridization solution was applied  
25 to a cover slip and then mounted onto an array slide. Hybridization was conducted in a  
humid hybridisation chamber, in a hybridization oven, at 60°C for 16 hours. Following  
hybridization the array slides were removed from their chamber and washed for 2 min in  
each of a 0.5X SSC and-0.1% w/v SDS, 0.5x SSC and 0.01% w/v SDS, 0.6x SSC and  
0.06% w/v SDS solution. The array slides were dried in a centrifuge for 1 min at 500xg.

**EXAMPLE 56*****Image Acquisition and Data Analysis***

Fluorescent images of the microarrays were acquired using a ScanArray Lite confocal laser  
5 scanner (Perkin Elmer) or GenePix 4000B scanner (Axon Instruments) and the images  
were analysed using GenePix Pro 4.0 and Acuity 2.0 (Axon Instruments) and GeneSight  
3.0 (BioDiscovery, Sunnyvale, CA). Slides were scanned for both Cy3 and Cy5 signal at a  
10  $\mu$ M pixel resolution. Laser intensity and amplification of the photomultiplier tubes were  
adjusted to ensure approximately equal overall signal intensity for both Cy3 and Cy5. Data  
10 obtained from the scanner was imported into Gene Pix Pro (Version 4.0, Axon  
Instruments). False colour images were generated for each dye and combined to provide a  
representation of the relative Cy3 and Cy5 intensities. Individual cDNA spots were flagged  
if spot size was too small, if the overall signal intensity was too low, or if the Cy3 and Cy5  
signal intensities within the spots were not linearly related. GenePix allows for the  
15 "flagging" of bad elements (defined by present GenePix parameters as feature signal  
intensity; feature background; element morphology; elements size and the percentage of  
pixels greater than feature background) that were then excluded from further analysis.

Median Cy3 and Cy5 signal intensities for each cDNA spot were imported from Genepix  
20 and data transformation conducted using Genesight (Version 3.0, BioDiscovery Inc, Los  
Angeles, USA). Signal intensities were corrected for local background and low expression  
values were omitted. The ratio of Cy3 to Cy5 was calculated and the data logarithmically  
transformed (base2). Signal intensity was normalized to the mean intensity of all respective  
signal intensities, providing a relative measure of gene expression for each element on the  
25 microarray slide. Gene expression analysis between control animals and animals separated  
for 4 days was assessed using an independent samples *t*-test. Differential gene expression  
as measured by microarray was screened for significance at  $p < 0.05$ .

Those skilled in the art will appreciate that the invention described herein is susceptible to  
30 variations and modifications other than those specifically described. It is to be understood  
that the invention includes all such variations and modifications. The invention also



## BIBLIOGRAPHY

Altschul *et al.*, *Nucl. Acids Res.* 25: 3389, 1997.

Antonenkova *et al.*, Isolation and subunit composition of native sterol carrier protein 2/3-oxoacyl-coenzyme A thiolase from normal rat liver peroxisomes. *Protein Expr Purif.* 18(3): 249-256, 2000.

Antonenkova *et al.*, Substrate specificities of 3-oxoacyl-CoA thiolase A and sterol carrier protein 2/3-oxoacyl-CoA thiolase purified from normal rat liver peroxisomes. Sterol carrier protein 2/3-oxoacyl-CoA thiolase is involved in the metabolism of 2-methyl-branched fatty acids and bile acid intermediates. *J Biol Chem.* 272(41): 26023-26031, 1997.

Atshaves *et al.*, Expression and intracellular processing of the 58 kDa sterol carrier protein-2/3-oxoacyl-CoA thiolase in transfected mouse L-cell fibroblasts. *J Lipid Res.* 40(4): 610-622, 1999.

Australian Institute of Health and Welfare (AIWH), Australia's Health, 2002, Canberra: AIWH.

Ausubel *et al.* "Current Protocols in Molecular Biology" John Wiley & Sons Inc, Unit 19.3, Chapter 15, 1994-1998.

Baker *et al.*, Similarity between the amino-terminal portion of mammalian 58-kD sterol carrier protein (SCPx) and Escherichia coli acetyl-CoA acyltransferase: evidence for a gene fusion in SCPx. *DNA Cell Biol* 10(9): 695-698, 1991.

Barnes *et al.*, The *Caenorhabditis elegans* behavioral gene unc-24 encodes a novel bipartite protein similar to both erythrocyte band 7.2 (stomatin) and nonspecific lipid transfer protein. *J. Neurochem.* 67(1): 46-57, 1996.

Barnett *et al.*, *Diabete Nutr. Metab.* 8: 42-47, 1995.

Barnett *et al.*, A cross-sectional and short-term longitudinal characterisation of NIDDM in *Psammomys obesus*. *Diabetologia* 37: 671-676, 1994a.

Barnett *et al.*, The effect of restricting energy intake on diabetes in *Psammomys obesus*. *Int. J. Obesity* 18: 789-794, 1994b.

Baum *et al.*, Regulation of sterol carrier protein-2 gene expression in rat liver and small intestine. *J Lipid Res.* 34(5): 729-739, 1993.

Bhattacharjee *et al.*, Genomic organization and chromosomal localization of the Asn1 gene, a mouse homologue of a bacterial arsenic-translocating ATPase gene. *Gene* 272: 291-299, 2001.

Bonner and Laskey, *Eur. J. Biochem.* 46: 83, 1974.

Bouchard, *The genetics of Obesity*, Boca Raton: CRC Press, 1994.

**Boulikroun *et al.*, Characterization of rat NDRG2 (N-myc downstream-regulated gene 2), a novel early mineralocorticoid-specific induced gene. *J. Biol. Chem.* 277(35): 31506-31515, 2002.**

Bun-ya *et al.*, Thiolas involved in bile acid formation. *J Biochem (Tokyo)* 123(2): 347-352, 1998.

Collier *et al.*, Development of obesity and insulin resistance in the Israeli sand rat (*Psammomys obesus*). Does leptin play a role? *Ann. New York Acad. Sci.* 827: 50-63, 1997a.

Collier *et al.*, *Exp. Clin. Endocrinol. Diabetes* 105: 36-37, 1997b.

- 97 -

DBH4 record from Pfam database of protein families Website, Sanger Centre  
[http://www.sanger.ac.uk/cgi-bin/Pfam/swisspfamget.pl?name=DHB4\\_HUMAN](http://www.sanger.ac.uk/cgi-bin/Pfam/swisspfamget.pl?name=DHB4_HUMAN)

Dunstan *et al.*, The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)--methods and response rates. *Diabetes Res. Clin. Pract.* 57: 119-129, 2002.

Ferdinandusse *et al.*, Peroxisomal fatty acid oxidation disorders and 58 kDa sterol carrier protein X (SCPx). Activity measurements in liver and fibroblasts using a newly developed method. *J Lipid Res.* 41(3): 336-342, 2000.

Festa *et al.*, Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. *51(4)*: 1131-1137, 2002.

Fuchs *et al.*, Disruption of the sterol carrier protein 2 gene in mice impairs biliary lipid and hepatic cholesterol metabolism. *J Biol Chem.* 276(51): 48058-48065, 2001.

Fuchs *et al.*, Sterol carrier protein 2 participates in hypersecretion of biliary cholesterol during gallstone formation in genetically gallstone-susceptible mice. *Biochem J.* 336(1): 33-37, 1998.

Hoffstedt *et al.*, The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity. *Diabetologia* 45(4): 584-587, 2002.

Human SCP-2 (NLTP\_HUMAN) record from SWISS-PROT database, ExPasy Website  
<http://kr.expasy.org/cgi-bin/niceprot.pl?P22307>

Interpro database of proteins <http://www.ebi.ac.uk/interpro/IEntry?ac=IPR003033>

- Ito *et al.*, Hepatic cholesterol metabolism in patients with cholesterol gallstones: enhanced intracellular transport of cholesterol. *Gastroenterology* 110(5): 1619-1627, 1996.
- Jiang *et al.*, Ahi-1, a novel gene encoding a modular protein with WD40-repeat and SH3 domains, is targeted by the Ahi-1 and Mis-2 provirus integrations. *J. Virol.* 76(18): 9046-9059, 2002.
- Kalaydjieva *et al.*, N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. *Am. J. Hum. Genet.* 67(1): 47-58, 2000.
- Kannenberg *et al.*, Aberrant oxidation of the cholesterol side chain in bile acid synthesis of sterol carrier protein-2/sterol carrier protein-x knockout mice. *J Biol Chem.* 274(50): 35455-35460, 1999.
- Kawata *et al.*, Modulation of cholesterol 7 alpha-hydroxylase activity by nonspecific lipid transfer protein in human liver--possibly altered regulation of its cytosolic level in patients with gallstones. *Clin Chim Acta.* 197(3): 201-208, 1991.
- Kopelman *et al.*, ASO consensus statement on obesity. UK Association for the Study of Obesity, *Int. J. Obesity* 18: 188-191, 1994.
- Kopelman, Obesity as a medical problem. *Nature* 404: 635-643, 2000.
- Kurdi-Haidar *et al.*, Isolation of the ATP-binding human homolog of the arsA component of the bacterial arsenite transporter. *Genomics* 36: 486-491, 1996.
- Kurdi-Haidar *et al.*, Biochemical characterization of the human arsenite-stimulated ATPase (hASNA-I). *J. Biol. Chem.* 273: 22173-22176, 1998a.
- Kurdi-Haidar *et al.*, Dual cytoplasmic and nuclear distribution of the novel arsenite-stimulated human ATPase (hASNA-I). *J. Cell. Biochem.* 71: 1-10, 1998b.

- Kurdi-Haidar *et al.*, Chromosomal localization and genomic structure of the human arsenite-stimulated ATPase (hASNA-I). *Somat. Cell Molec. Genet.* 24: 307-311, 1998c.
- Kurdi-Haidar *et al.*, Immunohistochemical analysis of the distribution of the human ATPase (hASNA-1) in normal tissues and its overexpression in breast adenomas and carcinomas. *J. Histochem. Cytochem.* 46:1243-1248, 1998d.
- Marmur and Doty, *J. Mol. Biol.* 5: 109, 1962.
- Marx, Unraveling the causes of diabetes. *Science* 296: 686-689, 2002.
- Mavri *et al.*, Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. *Diabetologia* 44(11): 2025-2031, 2001.
- McLean *et al.*, Altered ovarian sterol carrier protein expression in the pregnant streptozotocin-treated diabetic rat. *Biol Reprod.* 55(1): 38-46, 1996.
- Mertens and Van Gaal, Obesity, haemostasis and the fibrinolytic system. *Obes. Rev.* 3(2): 85-101, 2002.
- Mokdad *et al.*, The spread of the obesity epidemic in the United States, 1991-1998. *JAMA* 282(16): 1519-1522, 1999.
- Murphy and Schroeder, Sterol carrier protein-2 mediated cholesterol esterification in transfected L-cell fibroblasts. *Biochim Biophys Acta.* 1345(3): 283-292, 1997.
- Must *et al.*, The disease burden associated with overweight and obesity. *JAMA* 282(16): 1523-1529, 1999.

National Health and Medical Research Council, *Acting on Australia's weight: A strategy for the prevention of overweight and obesity*. Canberra: National Health and Medical Research Council, 1996.

Ohba *et al.*, The structure of the human sterol carrier protein X/sterol carrier protein 2 gene (SCP2). *Genomics* 24: 370-374, 1994.

Okuda and Kondoh, Identification of new genes ndr2 and ndr3 which are related to Ndr1/RTP/Drg1 but show distinct tissue specificity and response to N-myc. *Biochem. Biophys. Res. Commun.* 266(1): 208-215, 1999.

Olsen and Uhler, Inhibition of protein kinase-A by overexpression of the cloned human protein kinase inhibitor. *Molec. Endocr.* 5: 1246-1256, 1991.

Ossendorp *et al.*, Tissue-specific distribution of a peroxisomal 46-kDa protein related to the 58-kDa protein (sterol carrier protein x; sterol carrier protein 2/3-oxoacyl-CoA thiolase). *Arch Biochem Biophys.* 334(2): 251-260, 1996.

Pandolfi *et al.*, Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. *Arterioscler Thomb. Vasc. Biol.* 21(8): 1378-1382, 2001.

Puglielli *et al.*, Modulation of intrahepatic cholesterol trafficking: evidence by in vivo antisense treatment for the involvement of sterol carrier protein-2 in newly synthesized cholesterol transport into rat bile. *Biochem J.* 317(3): 681-687, 1996.

Qu *et al.*, Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. *Mol. Cell. Biochem.* 229(1-2): 35-44, 2002.

Ravussin, Metabolic differences and the development of obesity. *Metabolism* 44(3): 12-14, 1995.

Roff *et al.*, Deficiencies in sex-regulated expression and levels of two hepatic sterol carrier proteins in a murine model of Niemann-Pick type C disease. *J Biol Chem.* 267(22): 15902-15908, 1992.

Samad *et al.*, Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. *Mol. Med.* 6(8): 680-692, 2000.

Schroeder *et al.*, Probing the ligand binding sites of fatty acid and sterol carrier proteins: effects of ethanol. *Biochemistry.* 34(37): 11919-11927, 1995.

SCP2 Genecard record, Genecards Website, Weizmann Institute of Science  
<http://bioinfo.weizmann.ac.il/cards-bin/carddisp?SCP2&search=scp2&suff=txt>

SCP-2 record from Pfam database of protein families Website, Sanger Centre  
<http://www.sanger.ac.uk/cgi-bin/Pfam/getacc?PF02036>

Seedorf *et al.*, Defective peroxisomal catabolism of branched fatty acyl coenzyme A in mice lacking the sterol carrier protein-2/sterol carrier protein-x gene function. *Genes Dev.* 12(8): 1189-1201, 1998.

Seedorf *et al.*, Sterol carrier protein-2. *Biochim Biophys Acta.* 1486(1): 45-54, 2000.  
Review.

Shafrir and Gutman, *Psammomys obesus* of the Jerusalem colony: a model for nutritionally induced, non-insulin-dependent diabetes. *J. Basic Clin. Physiol. Pharm.* 4: 83-99, 1993.

Starodub *et al.*, Sterol carrier protein-2 localization in endoplasmic reticulum and role in phospholipid formation. *Am J Physiol Cell Physiol.* 279(4): C1259-1269, 2000.

Sterol Carrier Protein 2 record, OMIM Website <http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?184755>

Szyperski *et al.*, NMR determination of the secondary structure and the three-dimensional polypeptide backbone fold of the human sterol carrier protein 2. *FEBS Lett.* 335(1): 18-26, 1993.

Vaisanen *et al.*, Vaisanen SB, Humphries SE, Luong LA, Penttila I, Bouchard C, Rauramaa R. Regular exercise, plasminogen activator inhibitor-1 (PAI-1) activity and the 4G/5G promoter polymorphism in the PAI-1 gene. *Thomb. Haemost.* 82(3): 1117-1120, 1999.

van Heusden *et al.*, Chinese hamster ovary cells deficient in peroxisomes lack the nonspecific lipid transfer protein (sterol carrier protein 2). *J Biol Chem.* 265(7): 4105-4510, 1990.

Vesa *et al.*, Assignment of sterol carrier protein X/sterol carrier protein 2 to 1p32 and its exclusion as the causative gene for infantile neuronal ceroid lipofuscinosis. *Hum. Molec. Genet.* 3: 341-346, 1994.

Walder *et al.*, The effect of dietary energy restriction on body weight gain and the development of noninsulin-dependent diabetes mellitus (NIDDM) in *Psammomys obesus*. *Obesity Res.* 5: 193-200, 1997a.

Wanders *et al.*, Identification of the newly discovered 58 kDa peroxisomal thiolase SCPx as the main thiolase involved in both pristanic acid and trihydroxycholestanoic acid oxidation: implications for peroxisomal beta-oxidation disorders. *J Inherit Metab Dis.* 21(3): 302-305, 1998.

Wanders *et al.*, Sterol carrier protein X (SCPx) is a peroxisomal branched-chain beta-ketothiolase specifically reacting with 3-oxo-pristanoyl-CoA: a new, unique role for SCPx in branched-chain fatty acid metabolism in peroxisomes. *Biochem Biophys Res Commun.* 236(3): 565-569, 1997.

- 103 -

Welch *et al.*, Assignment of the mouse sterol carrier protein gene (Scp2) to chromosome 4. *Mammalian Genome* 7: 624-625, 1996.

Wirtz, Phospholipid transfer proteins revisited. *Biochem J.* 324(2): 353-360, 1997. Review.

World Trade Organisation. Obesity. Preventing and managing the global epidemic. Report of a WHO Consultation on Obesity. Geneva: World Health Organisation, 1998.

Yamamoto *et al.*, Cloning and expression of a cDNA encoding human sterol carrier protein 2. *Proc Natl Acad Sci USA.* 88(2): 463-467, 1991.

Yamamoto, Localization of human sterol carrier protein 2 gene and cDNA expression in COS-7 cells. *Hokkaido Igaku Zasshi* 67: 839-848, 1992.


Zanlungo *et al.*, Sterol carrier protein 2 gene transfer changes lipid metabolism and enterohepatic sterol circulation in mice. *Gastroenterology.* 119(6): 1708-1719, 2000.

Zhou *et al.*, Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. *Genomics* 73(1): 86-97, 2001.

Zimmet, Kelly West Lecture 1991. Challenges in diabetes epidemiology--from West to the rest. *Diabetes Care* 15: 232-252, 1992.


**ABSTRACT**

The present invention relates generally to a nucleic acid molecule which is expressed in at least red gastrocnemius muscle of *Psammomys obesus* under particular physiological conditions. It is proposed that the nucleic acid molecule is differentially expressed under differing conditions of obesity, anorexia, weight maintenance, diabetes and/or metabolic energy levels. More particularly, the present invention uses microarray technology to identify genes which are expressed under particular physiological conditions. It is proposed that the subject nucleic acid molecule and/or its expression product be used in therapeutic and diagnostic protocols for conditions such as obesity, anorexia, weight maintenance, diabetes and/or energy imbalance. The subject nucleic acid molecule and its expression product or derivatives, homologs, analogs and mimetics thereof are proposed to be useful, therefore, as therapeutic and diagnostic agents for obesity, anorexia, weight maintenance, diabetes and/or energy imbalance or as targets for the design and/or identification of modulators of their activity and/or function.




\* $p < 0.001$


**Figure 1**




**Figure 2**



**Figure 3**




**Figure 4**






\* $p=0.011$


**Figure 5**




\* $p=0.04$

**Figure 6**


**Figure 7****Figure 8****Figure 9**




**Figure 10**




**Figure 11**




**Figure 12**



**Figure 13**







**Figure 14**




\* $p < 0.001$

**Figure 15**


**Figure 16****Figure 17****Figure 18**




**Figure 19**



**Figure 20**




**Figure 21**




\* $p=0.035$ , # $p=0.007$

**Figure 22**







**Figure 23**



\* $p=0.001$


**Figure 24**

**Figure 25****Figure 26****Figure 27**




\* $p < 0.001$ , # $p < 0.001$


**Figure 28**



**Figure 29**




**Figure 30**




\* $p=0.037$




**Figure 31**




**Figure 32**




**Figure 33**


**Figure 34****Figure 35****Figure 36**




**Figure 37**




**Figure 38**



**Figure 39**




**Figure 40**









\* $p=0.01$


**Figure 41**




**Figure 42**

**Figure 43****Figure 44****Figure 45**


**Figure 46****Figure 47****Figure 48**



**Figure 49**







**Figure 50**




\* $p=0.016$

**Figure 51**


**Figure 52****Figure 53****Figure 54**



**Figure 55**




**Figure 56**




\* $p=0.021$

**Figure 57**



**Figure 58**



**Figure 59**

- 1 -

## SEQUENCE LISTING

<110> Autogen Research Pty Ltd  
Deakin University

<120> A novel gene and uses therefor

<130> 2595715/EJH

<140> Not yet available

<141> 2003-01-13

<160> 13

<170> PatentIn version 3.1

<210> 1

<211> 426

<212> DNA

<213> Psammomys obesus

<220>

<221> misc\_feature

<222> (336)..(366)

<223> n = any nucleotide sequence

<400> 1

```
ggacatcttt tcagccatga ggagctttct ggaaactcgg agttgatata gaaatatagg      60
aatataatca cgcaggctcc taacctggag aacattgagc tgtactggaa cagctacaac      120
aaccgccgag acctgaactt cgagcgaggt ggtgagatga ccctcaagtg ccctgtgatg      180
ctggtggttag gagaccaagc gcctcatgag gatgccgtgg tggagtgtaa ctcaaaactg      240
gacccacac agacctcggt cctcaagatg gctgattctg gaggtcagcc acagctgacc      300
cagccaggca agctgactga ggctttcaag tacttntctg aaggcatggg ctacatggcc      360
tctctctgca tgactcgctt atcgaggtct cgcacggcat ctttgaccag cgcagcatcc      420
attgat                                           426
```

<210> 2

<211> 451

<212> DNA

<213> Psammomys obesus

<400> 2

```
gctgggtaccg gtccggaatt cccgggatat cgtcgacca cgcgtccggt ggtggagaag      60
atcgctcctg ccgtgggttca cattgaactg tatcgcaaac ttcctttctc gaagagggag      120
gtgccagtgg cgagtgggtc cggatttatc gtgtctgagg atggactgat tgtgaccaat      180
```

- 2 -

gctcacgtgg tgaccaacaa aaacaggggtc aaggttgagc tgaagaatgg agcaacctat 240  
gaagctaaaa tcaaggatgt ggatgaaaag gcagacatcg cacttatcaa aattgaccac 300  
cagggaaagc tgccagtctt gctgctgggc cgctcctcag agcttcgacc aggagagttt 360  
gtggctgcca tcggaagccc cttttccctt caaaacacag tcaccactgg gatcgtcagt 420  
accaccacgc gaggcggcaa agagctgggg c 451

<210> 3  
<211> 478  
<212> DNA  
<213> Psammomys obesus

<400> 3  
tgacattttc tttccacctc ttatgatagc tgatatatac taaatcttta tacagaaatg 60  
tcagtacttg aacaaattca aaacacattg gtttattaac ttttggtca tgcattggttt 120  
attaggttca aattatacct gattcatcta tatttacttt taaaatgtgt ggtttcctca 180  
ttttaaaagt aaaactaaac agtgcttttg gaatttctaa gctactaatt gttgatagat 240  
acagcctgtg tctagtaaaa tagttttgtg ggtgtgggtt ctatctttcc atgaaaaagt 300  
gggaggtgta agtttagtttg gttagtgcct aatagttaaa tttatataaa ataagaatga 360  
gcatttggtg tctgtatgaa agggccctaa atcaaaatga ttatccataa tcaatcttta 420  
ttcttggttt ataaaaacca aagggcactc attggttaag tgtgctgaga tagaaaag 478

<210> 4  
<211> 1884  
<212> DNA  
<213> Psammomys obesus

<220>  
<221> misc\_feature  
<222> (609)..(609)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (611)..(611)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (1388)..(1388)  
<223> n = any nucleotide sequence

- 3 -

<220>  
<221> misc\_feature  
<222> (1390)..(1390)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (1413)..(1413)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (1512)..(1512)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (1568)..(1568)  
<223> n = any nucleotide sequence

<400> 4  
cgcagatact gcagagctga cgcattcttt gcctggcatc tcagcttgct aggtgtctca 60  
tcttcgctct gcgctcgtgg cctcctccaa ggctccagt ctctttaag aaaactcaag 120  
acctgggaag ctacgatgcg agcttgatgc cgctacccta gcaggctatg gacttcctga 180  
gggtcctcgg actgttgaca cccattccga tccgcatcct tccaagctga taagccggg 240  
accctagggc ggggtgcca gactcatgtg tgacgccttg cagtgaacc ccattcccag 300  
tgtggttgct tctttgctgg gctttggccc atttgatacc acgaaggatg acgatgctag 360  
ttatgcagca gccaacacac ctcccccaa ctctccgctg tctactggtg gccccactgt 420  
ccaggaagca ggtgtccgga actgacatct tggagcagag gggccatgag aggtgtgtgt 480  
atcctgccag aaagcagctg gaccacgacg ctccaagat gaaccactg tatacagagg 540  
catcatggga gttgttatgt caggagcatt ctagaccac gtgtacttga gcgtggaaag 600  
acagaagana ngcgcagaga ctggggcact tgatctgctc accatgatcg cctgcacggg 660  
tctcatccag ttctgcctt aggctacagt ggcggtgtcc acgggcttgc cattcaacgt 720  
gctctcagac ccagatcggg ctaccactg aggagaacct ttctactttg gtgggtatgc 780  
agaggaagg gtctcgactc cagagacctg gagtccaaag tttgtttttt ttattttacc 840  
agtaatttat ttattttttt tattattagt tatgagtcca aagtttaata ccattcaagc 900  
tactgctgtc tgtctgctta gagccacagc atgcaatgtg gcaccaaggc atccttgtcc 960

- 4 -

tcacagtttc acactgtggg aacaggcatc cttgttctta cagattagcg cgagggaaac 1020  
cagaaatatt aaacacgcag ggttgtctct ccaaaggag aggacatac cctgttttcc 1080  
tcccgaaggc tgggagcgga ggtgtttgat atcctggcta cctctgtgca atctgtaggc 1140  
catgtcctta agatgtagct gtcagtcggt agtggagccg gagccgtcag tcagtagatt 1200  
ggggttgtgg catgcgctt taactccatt taattccagc actctagtgg tttggtacag 1260  
cagcagcagc agcggttgca gtggcccgga gaagtcctga agaccagctt tcatccagc 1320  
actcaggcag caaaggcgga tggattctct gaggtcgagg ccggcctggg ctacagagtg 1380  
agtccagncn agccagggt acaacagaga aancctctct attgaaaaat aaataaatta 1440  
taaaaaaaaa aaggtgtcat gtgtcctgtg tactttacaa agaattgtga tgcttaagct 1500  
tttttgtgca cncaagaaaa ttgtttaact ggtgtcagac tcctgaagtt tgaaccagca 1560  
cttagccngg cgtgggtggc cagcctgta atcccagccc tcgggaggca gaggcagggtg 1620  
gatctctgag ttagaggcca gcctggtcta cagagtgagt ccaggacagc caggattaca 1680  
cagagaaacc ccgtctcaaa aatgtaaaat aaattaaaat aaagtttgaa ccaacagtgt 1740  
ttactgagtc gtgttgaaac agattacctt tttgcttctc tttgatcatt attctactgt 1800  
ggtgtcagca gagaccctc cagcaggtgg ccaacgtgag agtctcaagc ccgagaaggt 1860  
aagaatttaa aaaaaaaaaa aaaa 1884

<210> 5  
<211> 1358  
<212> DNA  
<213> Psammomys obesus  
  
<220>  
<221> misc\_feature  
<222> (385)..(385)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (416)..(416)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (430)..(430)  
<223> n = any nucleotide sequence

<220>

- 5 -

<221> misc\_feature  
<222> (507)..(507)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (754)..(754)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (856)..(856)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (928)..(928)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (980)..(980)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (1165)..(1165)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (1200)..(1200)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (1273)..(1273)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (1284)..(1284)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (1303)..(1303)  
<223> n = any nucleotide sequence

- 6 -

<220>  
<221> misc\_feature  
<222> (1305)..(1305)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (1326)..(1326)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (1330)..(1330)  
<223> n = any nucleotide sequence

<400> 5.  
gttgggaaag aatgaagaaa caaccgatg aatagaaatg aaaagcctaa gccaaatgga 60  
tttctgttga gatgttggat gaaaacaagt atccactgtt taccaacttg acgaaaaatc 120  
tcaactgagg tttggctgtt aaaaaaaaaa attcactgtg gcctctgtgc ttaattgtcg 180  
taaaccattg tgactgttac tgctcaaagt atcgactgtg tcattagtaa ctacatcaga 240  
attgcaccgc tgctgttggg aaagccaata aagaaacccc cagactgctg ctccagcaaat 300  
gttaataaag tgtgcgcacc gtaggcctgt ccaccagtc accaagcagc gtccttttgt 360  
ctgcgagtg ctgtgggtgt gattnaccac ctccagagggtg cacagcacct gcttgngcc 420  
ttaagtgtgn gtcagaagac aagcagcttc tcggtaacca acaacctgct tttcggagct 480  
cagtgttttag gctgtttact gaatcanata tgtaactcag cacacataag cgaagagaga 540  
ttttggctgc actggcaaga gtgaacccaaa tttacttcta ttttttaaag gcagatcata 600  
tttaagcata taagtaattt atggatataa attgttggat atttatttta gtctgaatat 660  
ttgtttttta attattacat gtgttctcta tgtctttatc tctggaataa cgatgccatt 720  
aaccacatgg ccatatgttt tgaaagtgg gtgnaacaga ggaaaagtca tccttcttgg 780  
ttcttgactc cctttcctca actacatgat aagtctatca ataaagcatt tgacctcagc 840  
aggggcagaa gcctgnaaag ttagaaaact cattgaccac agtagacaat tgatttctta 900  
gaaataagaa gtgagaagca gctgctgngc tgagcagggg atgtaaacca agtcagatg 960  
caccaacgtg aagaggcttn tagcaaaaat atgtttgcct ctcaacctg cacatgttct 1020  
agatgcttaa aaacagccac atggccccgc tgcgaggacc tcgtaatgtt gttgttgttg 1080

- 7 -

ttgttgttgt taaaggagtt ctcacaagcg tacaagtgca gcaactgaaag tggctgaggc 1140  
ccacagtcct cagcacccaa gtctnttccg cagcacgcca agctgggtgt gtccgggtgn 1200  
gtatgtctgt gctcagtgcc aagctgggtgt ttggtcccgt tgtatattat gtgccccaaag 1260  
tgttttgggg canagctgac ccangctgga cacacttctt ttngncttcg agtttactgg 1320  
ttgatncagn taaaaataaa ttaattaatt aaagactt 1358

<210> 6  
<211> 390  
<212> DNA  
<213> *Psammomys obesus*

<220>  
<221> misc\_feature  
<222> (3)..(3)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (9)..(9)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (60)..(60)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (71)..(71)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (91)..(91)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (113)..(113)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (388)..(388)  
<223> n = any nucleotide sequence

- 8 -

<220>  
<221> misc\_feature  
<222> (524)..(524)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (527)..(527)  
<223> n = any nucleotide sequence

<400> 6  
gtngaagc nt aggagttcga ggatgcgccc gatgtcgagc cgctggaacc cacgcttagc 60  
aatatcatcg agcagcgcag ccttaagtgg atcttcgctg ggggcaaggg tggcggttgg 120  
aagaccacct gcagctgcag cctggcggtc cagctgtcta agggacgtga gagtgttcta 180  
atcatttcca cagaccagc tcacaacatc tcagatgcat ttgaccagaa gttctccaag 240  
gtgcctacca aggtcaaagg ctatgacaac ctctttgcta tggagataga cccgagcctg 300  
ggcgtggcag agctccctga tgaagttctt cgaggaagac aacatgctga gcatgggcaa 360  
gaagatgatg caggaggcca tgagcgctt 390

<210> 7  
<211> 927  
<212> DNA  
<213> Psammomys obesus

<220>  
<221> misc\_feature  
<222> (524)..(524)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (527)..(527)  
<223> n = any nucleotide sequence

<400> 7  
aaaattttac aaatgagtgt gaattgcatt ctgatataat aattatcacc ccaccacact 60  
tttactgaca ctgttgatgg cctatgctgt gttttcacat cacaattctt gtatggaaaa 120  
atttctgtgg cctgtgtaac ccctctgggtc agtattatga aaccaactat ctttggtgat 180  
aaataagggt cgggtaagat gcccgagggt catgagtatg gcacaaataa cagaggacag 240  
gaggccttca cgacgaagga gcccgtaagt ggcctggagg gcacagatgc agttccaggt 300

- 9 -

caagaaaaga gcagcttttt caacaggcag tctgtgggta tgatgggaac tcagcctgtc 360  
tctgtagtta tggacagcgt ggcagggtgac tgtgccacata tcttcctata cagtgttttt 420  
tttttactga ctggaagtac gtgaatctca cttagtcccc aactggacgt tttctggaaa 480  
aaciaagcaa atgttaaagt atgtctttct ggatataggc cagnagnaaa tacattaaga 540  
atgagaggcc ttgctttgat ctcagccatt ggaggctaga aaaaaattga aaggaacctt 600  
cctgttgata gactcaaagc cgtgaacaga agcctcttgg cctgtttcag acaatctctg 660  
gtaatctact gacaatatcc aacagtttcg atgtccttgt ttaactaccc tggtagcttt 720  
cttgtggatt tgaagttcat ttttaaagct gtggaatttc aaactgaatt cacgtgcatt 780  
ttgtaaaagt tcagaaccag tgctgagtct gtgtggcagg tttttttcac cgcgtgatat 840  
actattacaa atgcatgtgg tgccatgctt gtcttcaa atataagtag tgctaaatgg 900  
ataagtcata tggagctttt gatttag 927

<210> 8  
<211> 374  
<212> DNA  
<213> Psammomys obesus  
  
<220>  
<221> misc\_feature  
<222> (60)..(60)  
<223> n = any nucleotide sequence

<400> 8  
tgagatagct actccataag cctctgaaga gcaatagcta atttattatt actgtaattn 60  
ttttaaaggc tttaaagtgc ctggtgggtt ccttgaaact aattttctac ttctgggatt 120  
ccctggattc tttataagag atggtgacat gactagggaa attctttttt tagtatgaaa 180  
attgtccctt caatactttt ctcttactgg cattgaatta tcacagagac agaaaattgg 240  
taattttttt aattttctaac tctccagaa aactcctctt gcctagtatt tatttgatgt 300  
gctttaacca tgggaggagg ggtggggggg gaactcattc aagctgccag tattttgatc 360  
tacaacctgt agca 374

<210> 9  
<211> 402  
<212> DNA  
<213> Psammomys obesus  
  
<220>  
<221> misc\_feature

- 10 -

<222> (71)..(71)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (91)..(91)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (113)..(113)  
<223> n = any nucleotide sequence

<220>  
<221> misc\_feature  
<222> (388)..(388)  
<223> n = any nucleotide sequence

<400> 9  
cccacgcagt ccgggtggct ctgcagcaca atttaggcct tggaggagct gtggttgtca 60  
ccctctacaa natgggcttc cccgaagcgg ncagctcctt cagaacacac canatttcgg 120  
ctgctccac cagctctgca agggatggat tcaaggccaa tcttgtcttt aaggagatcg 180  
agaagaagct tgaagaggaa ggggaacagt tcgtgaagaa gatcgggtggg atttttgcct 240  
tcaaagtga ggacggccct ggaggcaaag aagccacctg ggtggtggat gtgaagaatg 300  
gcaagggatc cgtgcttccc aactcagata agaaggctga ctgcacaatc accatggccg 360  
actccgactt gctggctctg atgactgnca aatgaaccc tc 402

<210> 10  
<211> 18  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer SP6

<400> 10  
atttaggtga cactatag 18

<210> 11  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> primer T7

- 11 -

<400> 11  
taatacgact cactataggg

20

<210> 12  
<211> 4  
<212> PRT  
<213> peptide

<400> 12

Glu Val Ser Cys  
1

<210> 13  
<211> 10  
<212> PRT  
<213> peptide

<400> 13

Gly Thr Arg Ser Arg Ser His Thr Ser Glu  
1 5 10

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:



**BLACK BORDERS**

- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**